{"text": "Our results show that both of these rejection groups were associated with inferior graft survival .The Kaplan - Meier estimate of the death - censored graft survival at 5 years post transplantation was 78 % and 81 % in the CR and SR groups , respectively , compared to 97 % in the control group without rejection .", "label": "", "metadata": {}, "score": "21.600685"}
{"text": "The actual pathogenetic role of these B - cell infiltrates remains to be established but the first studies and our own data indicate an inferior one - year allograft function and graft survival in patients with T - cell mediated rejections with B - cell infiltrates [ 9 - 11 ] .", "label": "", "metadata": {}, "score": "23.79658"}
{"text": "The 5-year estimated death - censored graft survival was 72 % for the borderline group , 83 % for the combined acute rejection group , and 97 % in the control group .", "label": "", "metadata": {}, "score": "24.815922"}
{"text": "Opposite to our finding , Gupta et al .[ 10 ] have reported that acute rejection episodes , delayed graft function , and one - year graft survival was similar between patients with and without HLA specificities defined by solid phase assay .", "label": "", "metadata": {}, "score": "26.33966"}
{"text": "When we classified the cause of graft loss for these 20 grafts , 35 % were attributed to progressive IFTA and 10 % to acute rejection .", "label": "", "metadata": {}, "score": "26.773293"}
{"text": "The 5-year estimate of the death - censored graft survival is 78 % in the CR and 81 % in the SR groups and 97 % in the control group without acute rejection ( log - rank . )", "label": "", "metadata": {}, "score": "26.789776"}
{"text": "In a single center study , Matas et al . showed that acute rejection occurring more than 1 year posttransplant was associated with a lower graft half - life for both living and deceased donor recipients [ 18 ] .", "label": "", "metadata": {}, "score": "26.847532"}
{"text": "In another single center study , Knight et al .demonstrated the impact of acute rejection on graft survival .Graft survival at 5 years posttransplant for recipients of living donors was 73 % for the rejection group and 90 % in the control group while for deceased donors , graft survival was 40 % in the rejection group and 88 % in the control group [ 25 ] .", "label": "", "metadata": {}, "score": "27.600311"}
{"text": "Clinical studies have shown that acute rejection , including subclinical acute rejection ( SR ) , is associated with inferior graft survival [ 5 , 10 , 11 ] , but all of these studies have been in patients on immunosuppression containing chronic corticosteroid .", "label": "", "metadata": {}, "score": "28.080055"}
{"text": "attributed 11.7 % of graft losses to acute rejection and 30.7 % to IFTA [ 23 ] , which is similar to the findings in our study .", "label": "", "metadata": {}, "score": "28.76941"}
{"text": "Four of the graft losses were attributed to nonadherence including 3 of the 9 in the control group .It is likely that these grafts had acute rejection but there was no biopsy confirmation so they were put in a separate category .", "label": "", "metadata": {}, "score": "28.912708"}
{"text": "Interestingly , only the early loss of previous graft showed a significant statistically association with the presence of preformed DSA and improved its predictive value of rejection .", "label": "", "metadata": {}, "score": "29.125473"}
{"text": "In another study of 589 deceased donor kidney recipients , Pirsch et al . showed that acute rejection was the single most important risk factor for subsequent graft loss .", "label": "", "metadata": {}, "score": "29.399473"}
{"text": "We measured the association of the rejection groups to death - censored graft survival using survival analysis .We compared unadjusted graft survival among the groups with Kaplan - Meier analysis and the log rank test .", "label": "", "metadata": {}, "score": "30.13675"}
{"text": "Only one out of nine factors studied was statistically different when we compared patients who suffered humoral and/or cellular acute rejection with recipients free from rejection .", "label": "", "metadata": {}, "score": "30.536232"}
{"text": "In a recent study of more than 28,000 deceased donor kidney transplant recipients , Opelz and D\u00f6hler showed that late acute rejection has a progressive negative impact on graft survival [ 10 ] .", "label": "", "metadata": {}, "score": "30.618885"}
{"text": "We also analyzed the number , class and MFI value of the pre - transplant DSA and no differences were found between patients with and without acute rejection .", "label": "", "metadata": {}, "score": "30.792027"}
{"text": "In our study the time interval from transplant to acute rejection did not appear to have an impact on death - censored graft survival .The Kaplan - Meier estimate of the 5-year graft survival was 81.8 % for those with acute rejection occurring greater than 180 days compared to 80.6 % in those with rejection occurring less than 180 days post transplantation ( HR 1.17 , CI 0.32 - 4.22 ) .", "label": "", "metadata": {}, "score": "30.87185"}
{"text": "But a small fraction of patients who are nonsensitized before transplant will develop de novo donor - specific HLA antibodies resulting in endothelial injury and a phenotype that is classified as antibody - mediated rejection [ 6 ] .", "label": "", "metadata": {}, "score": "31.803288"}
{"text": "In addition , there was a larger proportion of patients in both rejection groups with the combination of IFTA and persistent inflammation on the followup protocol biopsy done at 1 year ( Table 4 ) .", "label": "", "metadata": {}, "score": "31.947388"}
{"text": "For this analysis we combined the two rejection groups and determined the graft survival for patients with rejection occurring more than 180 days compared to those with rejection occurring less than 180 days post transplantation .", "label": "", "metadata": {}, "score": "32.019024"}
{"text": "A total of 27 patients without B - cell infiltration had a mean increase over the baseline function before the rejection in the GFR of 2.5 ml / min ( \u00b1 24.5 standard deviation ) one year after treatment of the rejection episode .", "label": "", "metadata": {}, "score": "32.05419"}
{"text": "It is also possible that our study is merely underpowered to show the difference in graft survival for late rejection .As a result the true differences in the time of onset of the acute rejection may be less than we estimate .", "label": "", "metadata": {}, "score": "32.83299"}
{"text": "Previous studies have shown a similar impact of acute rejection on graft survival [ 5 , 24 , 25 ] .In a study of patients getting protocol biopsies at two weeks post transplantation , Choi et al . showed that acute rejection was associated with inferior graft survival [ 5 ] .", "label": "", "metadata": {}, "score": "32.913925"}
{"text": "Despite this , our study showed a 0 to 1 ( versus 2 ) HLA - B mismatch to be a predictor of 10-year graft survival ; HLA - A and HLA - DR mismatches had no statistical significance .", "label": "", "metadata": {}, "score": "32.93664"}
{"text": "found that acute rejection occurring more than 3 months post transplantation had a greater negative impact on graft survival [ 19 ] .There are some possible explanations for the lack of an impact of late rejection on graft survival in our study .", "label": "", "metadata": {}, "score": "32.99623"}
{"text": "Moreover , the majority of the cases were biopsied during the followup .Patients with positives DSA in the pre - transplant sera showed a worse prognosis than subjects without DSA .", "label": "", "metadata": {}, "score": "33.077522"}
{"text": "NO AR : control group without rejection , SR : subclinical rejection , CR : clinical rejection .The occurrence of death with a functioning graft was not different between the three groups but death - censored graft loss was higher in the two rejection groups ( Table 5 ) .", "label": "", "metadata": {}, "score": "33.46227"}
{"text": "The positive predicted value of HLA - DSA in relation to rejection reached 100 % if patients lost their previous graft in the first year after transplant .", "label": "", "metadata": {}, "score": "33.718983"}
{"text": "However , there is increasing evidence that intragraft B - cells are also important in the T - cell - mediated rejections .First , a significant proportion of patients with acute T - cell - mediated rejection have B - cells present in the infiltrates .", "label": "", "metadata": {}, "score": "33.75188"}
{"text": "The primary efficacy endpoint in both studies was the incidence of death , graft loss or an episode of acute rejection during the first 6 months post - transplantation .", "label": "", "metadata": {}, "score": "33.77344"}
{"text": "Causes of Graft Failure .The causes of graft failure are shown in Table 6 .If it is assumed that graft losses from IFTA ( . ) are the phenotypes of immune graft losses , then 64 % of the grafts lost in the two rejection groups are potentially immune related compared to 22 % in the control group , but this difference was not statistically significant .", "label": "", "metadata": {}, "score": "34.00363"}
{"text": "Intragraft cytokine and chemokine profiles were assessed .Graft - infiltrating cells were examined histologically .Parenchymal rejection and CAV was significantly attenuated in donor hearts transplanted into IL-16(-/- ) recipient mice compared with WT controls .", "label": "", "metadata": {}, "score": "34.177338"}
{"text": "The following patients were excluded : combined organ transplant recipients , patients with pretransplant donor - specific antibody ( DSA ) or positive flow cross - match , and recipients who lost the graft within 30 days of transplantation .", "label": "", "metadata": {}, "score": "34.23549"}
{"text": "In Study 4 , the percentage of patients experiencing biopsy - proven acute rejection by 6 months was 15 % ( 9 of 59 patients ) in the Simulect group and 27 % ( 17 of 64 patients ) in the placebo group .", "label": "", "metadata": {}, "score": "34.413918"}
{"text": "-/- ) recipient mice ( H-2b ) .Overall graft survival was monitored .Graft infiltrating cell profile , including ? ?T cell subtype , cytokine expression , and myeloperoxidase activity were measured by flow cytometry , TaqMan ( Applied Biosystems , Carlsbad , CA ) polymerase chain reaction , and myeloperoxidase assay , respectively , on postoperative days 3 and 6 .", "label": "", "metadata": {}, "score": "34.587723"}
{"text": "In particular , early acute rejection , frequent acute rejection episodes , and refractory acute rejection can drastically affect long - term survival of a renal graft [ 7 , 13 , 14 ] .", "label": "", "metadata": {}, "score": "34.908688"}
{"text": "Since the aim of the study was to determine the impact of acute rejection on graft outcome , grafts lost during the first 30 days related to technical reasons were excluded from the analysis .", "label": "", "metadata": {}, "score": "34.968575"}
{"text": "There was no difference in the rate of delayed graft function , patient survival , or graft survival between Simulect - treated patients and placebo - treated patients in either study .", "label": "", "metadata": {}, "score": "35.01007"}
{"text": "In our study , recipient positivity for CMV IgG was statistically different between the groups and correlated with better long - term graft survival .Paired donor - recipient serology was not analyzed .", "label": "", "metadata": {}, "score": "35.400856"}
{"text": "A previous report showed that an episode of acute rejection reduced from 12.5 to 6.6 years the kidney graft half - life [ 7 ] .", "label": "", "metadata": {}, "score": "35.862312"}
{"text": "The Kaplan - Meier estimate of graft survival at 5 years posttransplant was 78 % and 81 % for the CR and SR groups , respectively , compared to 97 % for the control group .", "label": "", "metadata": {}, "score": "36.402786"}
{"text": "Our analysis showed a graft survival rate of 71.5 % after ten years of follow - up .This increase has been mostly attributed to improvements in first - year survival [ 9 ] .", "label": "", "metadata": {}, "score": "37.2534"}
{"text": "But at 5 years , patient and graft survival and GFR were not different between the groups .However , none of these studies have evaluated the impact of acute rejection , particularly SR , on graft survival .", "label": "", "metadata": {}, "score": "37.71363"}
{"text": "Data analysis indicated that an optimal first year graft function ( including absence of acute rejection episodes and creatinine level at 12 months ) was of paramount importance for long - term graft survival .", "label": "", "metadata": {}, "score": "37.989296"}
{"text": "Taken together , our results in the acute and chronic rejection studies suggest a potential cardioprotective mechanism for metformin ; we demonstrate a correlation between metformin - induced decrease in acute I - R injury and metformin - related decrease in chronic rejection .", "label": "", "metadata": {}, "score": "38.12183"}
{"text": "Subjects and Methods .Study Design .This is a retrospective study to analyze the role of preformed antibodies in solid organ rejection .No desensitization protocol was performed .", "label": "", "metadata": {}, "score": "38.59602"}
{"text": "This relationship was not found for recipient age .There is a long - standing debate about whether delayed graft function reduces the survival rate of a renal graft [ 7 ] .", "label": "", "metadata": {}, "score": "38.608356"}
{"text": "A total of 180 patients will be recruited .Discussion .It is important to clarify the relevance of anti - B cell targeting in T - cell mediated rejection and answer the question whether this novel concept should be incorporated in the conventional anti - rejection therapy .", "label": "", "metadata": {}, "score": "38.63393"}
{"text": "All HS subjects received the same induction therapy and rejection episodes were biopsy proven .Thirteen patients ( 56.5 % ) preformed HLA - DSA , and we observed higher incidence of acute rejection in aforementioned patients than in the pre - transplant negatives DSA recipients ( 77 % versus 30 % , .", "label": "", "metadata": {}, "score": "38.78277"}
{"text": "In the present study , we investigated the role of IL-17 in acute allograft rejection using IL-17-deficient mice .Donor hearts from FVB mice were heterotopically transplanted into either C57BL/6J - IL-17-deficient ( IL-17(-/- ) ) or -wild - type mice .", "label": "", "metadata": {}, "score": "38.805473"}
{"text": "Statistical evaluation .The primary endpoint of the induction - therapy comparison ( biopsy - proven acute rejection occurring before maintenance - therapy randomization or at 6 months post - transplant ( whichever occurs first ) will be compared using the log - rank test , with average event rate ratios derived using standard methods [ 27 ] .", "label": "", "metadata": {}, "score": "38.83831"}
{"text": "Since the number of retransplanted patients is increased year by year , the study of anti - HLA antibodies using a method which can improve sensitivity and specificity to detect donor specific anti - HLA - antibodies ( DSA ) would be useful in order to avoid the acute rejection .", "label": "", "metadata": {}, "score": "38.917324"}
{"text": "The remaining 375 patients without rejection served as the control group .The mean HLA mismatch was significantly higher in the CR group compared to the no rejection group ( 3.94 versus 3.33 , . ) , but not for the SR group ( 3.74 ) .", "label": "", "metadata": {}, "score": "39.378624"}
{"text": "In addition , the rejections in the SR group were milder and occurred later after transplantation compared to the CR group ( Table 3 and Figure 1 ) .", "label": "", "metadata": {}, "score": "39.39036"}
{"text": "If a follow - up B - cell count in these patients reveals B - cells numbers above the target value , these patients will be excluded from the study .", "label": "", "metadata": {}, "score": "39.510277"}
{"text": "The negative impact of these antibodies was even higher when patients suffered an early loss of the previous transplant .Introduction .A best knowledge of immune system and the introduction of several immunosuppressive agents have led to reduce the incidence of acute rejection ( AR ) but had a limited impact on long - term allograft survival [ 1 ] .", "label": "", "metadata": {}, "score": "39.591606"}
{"text": "Subjects in both studies continued to receive a dual - therapy regimen with cyclosporine , USP ( MODIFIED ) and corticosteroid .No difference was observed between groups in the 5-year graft survival in either Study 1 ( 91 % Simulect group , 92 % placebo group ) or Study 2 ( 85 % Simulect group , 86 % placebo group ) .", "label": "", "metadata": {}, "score": "39.742958"}
{"text": "Yet , Boom et al . reported that delayed graft function did not affect the long - term survival rate of recipients they examined [ 20 ] .", "label": "", "metadata": {}, "score": "40.011097"}
{"text": "For the screening , the biopsies will be stained for CD20 , C4d and SV40 in the above described fashion , in addition to the normal chemical stainings performed in each center for the rejection diagnosis .", "label": "", "metadata": {}, "score": "40.212566"}
{"text": "All patients who received a living or deceased donor kidney transplant and were treated with RSW were included .The primary outcome was death - censored graft survival .", "label": "", "metadata": {}, "score": "40.47644"}
{"text": "A comparative analysis of the efficacy of different cell candidates for the treatment of heart disease remains to be described .Cell survival was measured by BLI and by TaqMan PCR .", "label": "", "metadata": {}, "score": "40.508026"}
{"text": "Significant predictors of long term graft survival were lower 12-month PT creatinine ( . )Our results show that an early KT , younger donor age , and an optimal first year graft function are of paramount importance for long - term graft survival .", "label": "", "metadata": {}, "score": "40.627426"}
{"text": "The general perception is that successfully treated acute T - cell mediated rejections do not harm the graft significantly .Yet , in clinical experience not all patients will recover with full function after the anti - rejection treatment .", "label": "", "metadata": {}, "score": "40.7244"}
{"text": "The histological appearances of cellular rejection after depleting induction with alemtuzumab are usually typical ( despite the profound lymphopenia ) [ 24 ] .All reports of rejection ( including events that may yield a diagnosis of rejection ( for example , transplant biopsy ) will be adjudicated by trained clinicians , blinded to study treatment allocation , at the coordinating center .", "label": "", "metadata": {}, "score": "40.74443"}
{"text": "At the half - year visit after randomization ( Day 182 \u00b1 28 ) , B - cell counts and laboratory tests will be repeated in all patients .", "label": "", "metadata": {}, "score": "40.84345"}
{"text": "During the early posttransplant period ( 6 months ) , HLA - DR mismatches have a stronger influence on graft survival than HLA - A or B mismatches which have a very small influence .", "label": "", "metadata": {}, "score": "40.87578"}
{"text": "The small number of participants who are randomized but not transplanted will be censored at day 0 for the purposes of analysis .Secondary endpoints for which time - to - event data are available will be compared with the log - rank test , whereas other categorical endpoints will be compared with \u03c7 2 tests .", "label": "", "metadata": {}, "score": "40.88358"}
{"text": "Our findings suggest novel therapeutic strategies for minimizing chronic cardiac rejection via the use of metformin- and AMPK - mediated pathways to suppress acute I - R injury .", "label": "", "metadata": {}, "score": "41.028343"}
{"text": "Both randomizations use a minimization algorithm that ensures balance for recipient age , ethnicity , type of transplant , human leukocyte antigen mismatch , sensitization status ( and for maintenance randomization , allocated induction therapy ) .", "label": "", "metadata": {}, "score": "41.059067"}
{"text": "Functional studies significantly underestimate the incidence of histological graft injury , with one study showing that 94 % of grafts had histological evidence of IF / TA at one year [ 4 ] .", "label": "", "metadata": {}, "score": "41.160393"}
{"text": "In this randomized prospective study , 10 children with acute T - cell mediated rejection with B - cell infiltrates were treated with rituximab in addition to standard - of - care anti - rejection treatment ( steroid boli and/or thymoglobuline ) .", "label": "", "metadata": {}, "score": "41.172794"}
{"text": "Figure 2 : Relationship between early loss of previous transplant , preformed DSA against the new graft , and incidence of rejection .PrDSA : performed DSA .", "label": "", "metadata": {}, "score": "41.453587"}
{"text": "Composite Endpoint for Efficacy Failure Within 12 Months of Randomization : Death , Graft Failure , Biopsy - proven Acute Rejection or Loss to Follow - up .", "label": "", "metadata": {}, "score": "41.485046"}
{"text": "Patients with an episode of acute rejection requiring antibody therapy within 3 months before Screening .Patients treated for acute rejection within 30 days before Screening .", "label": "", "metadata": {}, "score": "41.56987"}
{"text": "Here , we report the 6-year follow - up of 30 patients prospectively recruited to this single - arm pilot study and compare outcomes to a matched contemporaneous control group of 30 patients who received standard induction and calcineurin - inhibitor - based immunosuppression .", "label": "", "metadata": {}, "score": "41.61158"}
{"text": "Given these facts , the current treatment of acute T - cell mediated rejection may be suboptimal in many cases .One possible explanation could be that this type of rejection is more complex than reflected by current schemes and that therapy with steroids alone does not fully address this complexity .", "label": "", "metadata": {}, "score": "41.65683"}
{"text": "Total number of anti - rejection treatments .Patients switched from assigned therapy due to rejection or side effects .Patients needing steroids because of rejection .", "label": "", "metadata": {}, "score": "41.65981"}
{"text": "Rejection rates in the first 6 months were similar in alemtuzumab ( 6.6 % ) and control groups ( 10 % ) .A higher than expected incidence of rejection in the alemtuzumab group following cessation of mycophenolate at 1 year ( 17 % ) was mitigated in later patients by retaining low dose mycophenolate .", "label": "", "metadata": {}, "score": "41.881798"}
{"text": "Abstract .Although ? ?T cells are known to participate in the development of acute cardiac allograft rejection , the role of ? ?T cells remains poorly understood .", "label": "", "metadata": {}, "score": "42.181335"}
{"text": "Discussion .In this study of kidney transplant recipients treated with a rapid steroid withdrawal protocol clinical acute rejection occurred in 7.8 % of patients which is similar to previous studies of early steroid withdrawal [ 13 , 14 ] .", "label": "", "metadata": {}, "score": "42.3048"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. S\u00fcsal , J. Ovens , K. Mahmoud et al . , \" No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive luminex single - antigen testing : a collaborative transplant study report , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "42.603867"}
{"text": "There were some differences in the treatment of the rejections between the groups which may have influenced the outcome .For example , the average number of doses ( 2.5 versus 1.7 ) and average total dose of pulse corticosteroids in mg ( . ) were higher in the CR group compared to the SR group .", "label": "", "metadata": {}, "score": "42.638496"}
{"text": "Utilizing a murine heterotopic heart transplant model system , IL-17-deficient recipient mice had decreased allograft inflammatory cell recruitment , decreased IL-6 , MCP-1 , and KC production , and reduced graft coronary artery disease ( GCAD ) .", "label": "", "metadata": {}, "score": "42.702477"}
{"text": "Beneficial effects of targeting B cells in T - cell - mediated acute rejection with rituximab can be based on the concept that allospecific T - cell / B - cell cross - talk in secondary lymphatic organs .", "label": "", "metadata": {}, "score": "42.752586"}
{"text": "It was first studied in kidney transplantation as a potential treatment for acute rejection .In a small non - randomized pilot study of 12 patients , it appeared to be effective , but was associated with severe infective episodes [ 6].", "label": "", "metadata": {}, "score": "43.244766"}
{"text": "The effector response results in inflammation , epithelial dedifferentiation , and epithelial - to - mesenchymal transition with subsequent graft fibrosis [ 4 ] .Acute rejection can cause graft dysfunction and be clinically apparent , or it can be clinically silent and found only by surveillance biopsy [ 4 , 5 ] .", "label": "", "metadata": {}, "score": "43.381664"}
{"text": "Clinical trials gov .number : NCT01117662 .Keywords .Cellular kidney allograft rejection B - cells Rituximab .Background .High dose steroid therapy is standard - of - care for treating acute T - cell mediated rejection of renal allografts , along with intensified maintenance immunosuppressive therapy in some cases ( KDIGO - Guidelines [ 1 ] ) .", "label": "", "metadata": {}, "score": "43.40161"}
{"text": "From 23 HS recipients , 22 were retransplanted and the 56 % showed HLA - DSA in the the day - of - transplant sera with mean fluorescence intensity ( MFI ) of 6000 ( 3345 - 8990 ) .", "label": "", "metadata": {}, "score": "43.522297"}
{"text": "A 2-year follow - up of patients in the PARTNER trial supports TAVR as an alternative to surgery in high - risk patients .", "label": "", "metadata": {}, "score": "43.71788"}
{"text": "least 2.5 years after transplantation ) .Thus , of 800 patients entering the study , about 530 ( two- thirds ) would be re - randomized at 6 months .", "label": "", "metadata": {}, "score": "44.063675"}
{"text": "Background .Acute kidney allograft rejection is a major cause for declining graft function and has a negative impact on the long - term graft survival .", "label": "", "metadata": {}, "score": "44.079018"}
{"text": "Recipient and donor information was collected from our computed database .We included , in our analysis , all recipients with a graft survival beyond 3 months , and patients surviving beyond the first - year PT .", "label": "", "metadata": {}, "score": "44.09204"}
{"text": "618 - 622 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Loupy , C. Suberbielle - Boissel , G. S. Hill et al . , \" Outcome of subclinical antibody - mediated rejection in kidney transplant recipients with preformed donor - specific antibodies , \" American Journal of Transplantation , vol .", "label": "", "metadata": {}, "score": "44.215034"}
{"text": "It is clear that the implication of pre - transplant DSA in kidney allograft loss must be focused in causes due to immune system .In these cases we would be able to talk about \" DSA susceptible patients \" who are more sensitive to foreign HLA antigens and usually the graft loss occurs in a period of time lower than a year .", "label": "", "metadata": {}, "score": "44.275997"}
{"text": "The primary objective is to show that additional anti - rejection treatment with rituximab is more efficacious than the standard anti - rejection treatment with regard to the allograft function one year after these treatments .", "label": "", "metadata": {}, "score": "44.29136"}
{"text": "Independent from the study protocol , all patients will receive steroid boli for rejection therapy .B - cell infiltrates in the biopsies are considered significant in the RIACT study , when more than X400 are found .", "label": "", "metadata": {}, "score": "44.356453"}
{"text": "Although all efforts will be done to achieve complete data for the primary endpoint for all patients , two additional patients will be recruited per treatment group to ascertain sufficient numbers of patients in each group .", "label": "", "metadata": {}, "score": "44.410694"}
{"text": "Abstract .IL-16 promotes the recruitment of various cells expressing CD4 , a receptor for IL-16 .Grafts were harvested at 52 days , parenchymal rejection was assessed by the ISHLT grading system , and CAV was examined morphometrically .", "label": "", "metadata": {}, "score": "44.4673"}
{"text": "P -values will be assessed descriptively .Discussion .Acute T - cell mediated tubulointerstitial rejections occur in 15 to 30 % of all transplanted patients .", "label": "", "metadata": {}, "score": "44.67523"}
{"text": "However , no significant effects on neovascularization were observed , as monitored by LDPI and histology .This is one of the first studies to assess kinetics of transplanted MNCs in PAD using in vivo molecular imaging .", "label": "", "metadata": {}, "score": "44.86257"}
{"text": "Depleting induction agents profoundly reduce the number of circulating lymphocytes capable of mounting an immune response during this period .It has been suggested that by the time the peripheral lymphocytes return , the graft may have recovered from the injury , and will therefore be immunologically quiescent [ 17 ] .", "label": "", "metadata": {}, "score": "44.95956"}
{"text": "Depleting induction agents profoundly reduce the number of circulating lymphocytes capable of mounting an immune response during this period .It has been suggested that by the time the peripheral lymphocytes return , the graft may have recovered from the injury , and will therefore be immunologically quiescent [ 17].", "label": "", "metadata": {}, "score": "44.95956"}
{"text": "Abstract .Mast cells are hypothesized to promote rejection and adverse remodeling in cardiac allografts .In contrast , it has been reported that mast cells may enhance cardiac allograft survival in rats .", "label": "", "metadata": {}, "score": "45.24714"}
{"text": "The primary analyses will be conducted on the intention - to - treat ( ITT ) population .Patients without complete B - cell depletion will also be observed and assessed according to the study protocol .", "label": "", "metadata": {}, "score": "45.289642"}
{"text": "Abstract .Clinical trials of bone marrow - derived stem cell therapy for the heart have yielded variable results .The basic mechanism(s ) that underlies their potential efficacy remains unknown .", "label": "", "metadata": {}, "score": "45.32556"}
{"text": "All analyses will be intention to treat , and will include all randomized participants who are transplanted .The small number of participants who are randomized but not transplanted will be censored at day 0 for the purposes of analysis .", "label": "", "metadata": {}, "score": "45.333252"}
{"text": "The primary efficacy endpoint of the study is the change of the glomerular filtration rate ( GFR ) one year after intervention compared to the baseline GFR before the rejection episode .", "label": "", "metadata": {}, "score": "45.370422"}
{"text": "Q - VD - OPh treatment led to a significant reduction in aneurysm size and decreased extracellular matrix degradation in the aortic wall compared with control mice .", "label": "", "metadata": {}, "score": "45.405643"}
{"text": "In a large retrospective study , S\u00fcsal et al .[ 11 ] have reported also no association of kidney graft loss with anti - HLA antibodies detected by LSA .", "label": "", "metadata": {}, "score": "45.419422"}
{"text": "Acute rejection included both cellular rejection and antibody - mediated rejection .Biopsies showing Banff borderline changes were included in the rejection groups .Clinical rejection ( CR ) included all rejections found on biopsies done for cause and associated with a creatinine increase of more than 23 \u03bc mol / L and subclinical rejection ( SR ) included with a serum creatinine that was within 23 \u03bc mol / L of the previous baseline .", "label": "", "metadata": {}, "score": "45.492954"}
{"text": "726 - 728 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. J. Knight , L. Burrows , and C. Bodian , \" The influence of acute rejection on long - term renal allograft survival : a comparison of living and cadaveric donor transplantation , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "45.677166"}
{"text": "Other Names : .Protocol synopsis Title An open , single centre , pilot study to investigate a steroid free immunosuppressive regimen for de novo renal transplant recipients followed by a two arm randomization to a calcineurin inhibitor containing and a calcineurin inhibitor free maintenance immunosuppression after three months .", "label": "", "metadata": {}, "score": "45.746468"}
{"text": "Published studies to date have been controversial [ 8 - 12 ] .Several authors have pointed out that the successful allocations of suitable renal allograft have been possible in sensitized patients as a result of the detection and definition of alloantibodies with a higher degree of sensitivity and specificity [ 13 , 14 ] .", "label": "", "metadata": {}, "score": "45.92097"}
{"text": "10 , pp .2464 - 2472 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . F. Moreso , M. Ibernon , M. Gom\u00e0 et al . , \" Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss , \" American Journal of Transplantation , vol .", "label": "", "metadata": {}, "score": "46.052948"}
{"text": "For example , graft failure and cancer ( with the possible exception of post - transplant lymphoproliferative disorder ) will be uncommon during the first few years after transplantation , when most studies cease follow - up .", "label": "", "metadata": {}, "score": "46.306973"}
{"text": "If the optimistic assumption for the sample size calculation holds true , the study has a chance of approximately 60 % to reject the null hypothesis at the time of the interim analysis and thus ended at this point .", "label": "", "metadata": {}, "score": "46.327682"}
{"text": "In another two independent cohorts ( 151 renal transplant biopsies ) , the CRM genes correlated with the extent of graft injury and predicted future injury to a graft using protocol biopsies .", "label": "", "metadata": {}, "score": "46.4942"}
{"text": "Therefore , IL-17 neutralization may provide a potential target for novel therapeutic treatment for cardiac allograft rejection .Long - Term Durability of Open Thoracic and Thoracoabdominal Aneurysm Repair SEMINARS IN VASCULAR SURGERY Fischbein , M. P. , Miller , D. C. 2009 ; 22 ( 2 ) : 74 - 80 .", "label": "", "metadata": {}, "score": "46.532646"}
{"text": "Finally , V ? 1 + and V ? 4 + T cells did not produce IL-17 , although both represent 20 % to 30 % total graft infiltrating ? ?", "label": "", "metadata": {}, "score": "46.567837"}
{"text": "In our study , death with a function graft accounted for 47 % [ 18 ] of the grafts lost .This is similar to the study by El - Zoghby et al . , where they attributed 43 % of grafts lost to DWFG [ 23 ] .", "label": "", "metadata": {}, "score": "46.583885"}
{"text": "Patients successfully withdrawn from calcineurin inhibitor at three months .Graft survival .Patient survival .Safety : .Graft survival .Patient survival .Protocol biopsies at 3 months ( range : day 75 to 105 ) and 6 months ( range day 165 to 195 ) sub clinical rejection .", "label": "", "metadata": {}, "score": "46.60772"}
{"text": "- 887 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. M. Van Den Berg - Loonen , E. V. A. Billen , C. E. M. Voorter et al . , \" Clinical relevance of pretransplant donor - directed antibodies detected by single antigen beads in highly sensitized renal transplant patients , \" Transplantation , vol . 85 , no . 8 , pp .", "label": "", "metadata": {}, "score": "46.702766"}
{"text": "All reports of rejection ( including events that may yield a diagnosis of rejection ( for example , transplant biopsy ) will be adjudicated by trained clinicians , blinded to study treatment allocation , at the coordinating center .", "label": "", "metadata": {}, "score": "46.744514"}
{"text": "Official Title : .Open , Single Centre , Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for De Novo Renal Transplant Recipients Followed by Randomisation to Calcineurin Inhibitor Containing or Calcineurin Inhibitor Free Immunosuppression .", "label": "", "metadata": {}, "score": "46.79167"}
{"text": "Discussion .Page 4 .Late graft failure is a major issue for kidney - transplant recipients .If our hypothesis that minimizing CNI exposure with Campath - based induction therapy and/or an elective conversion to sirolimus - based maintenance therapy can improve long - term graft function and survival is correct , then patients should experience better graft function for longer .", "label": "", "metadata": {}, "score": "46.8447"}
{"text": "The CONCEPT study randomized 192 kidney - transplant recipients to remain on a ciclosporin - based regimen or to switch to a sirolimus - based regimen at 3 months after transplantation .", "label": "", "metadata": {}, "score": "46.91136"}
{"text": "10.1056/NEJMoa067411 .View Article .Friend PJ , Rebello P , Oliveira D , Manna V , Cobbold SP , Hale G , Jamieson NV , Jamieson I , Calne RY , Harris DT : Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody .", "label": "", "metadata": {}, "score": "46.916214"}
{"text": "859 - 866 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. B. Dunn , H. Noreen , K. Gillingham et al . , \" Revisiting traditional risk factors for rejection and graft loss after kidney transplantation , \" American Journal of Transplantation , vol .", "label": "", "metadata": {}, "score": "47.010387"}
{"text": "6 , pp .1354 - 1360 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. G. Hidalgo , P. M. Campbell , B. Sis et al . , \" De novo donor - specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure , \" American Journal of Transplantation , vol .", "label": "", "metadata": {}, "score": "47.06499"}
{"text": "Follow - up averaged 4.7 \u00b1 3.3 years ( 1102 patient - years ) .Freedom from adverse outcomes was determined using log - rank calculations .", "label": "", "metadata": {}, "score": "47.189445"}
{"text": "2529 - 2531 , 2012 .View at Publisher \u00b7 View at Google Scholar The main purpose of this study is to investigate , whether a steroid free immunosuppressive treatment is a valuable alternative in the treatment of de novo kidney transplant recipients and if it is possible to withdraw calcineurin inhibitors after 3 months .", "label": "", "metadata": {}, "score": "47.19033"}
{"text": "10 , pp .1377 - 1381 , 2002 .View at Google Scholar \u00b7 View at Scopus . A. Piazza , E. Pocci , L. Borrelli et al . , \" Impact of donor - specific antibodies on chronic rejection occurrence and graft loss in renal transplantation : posttransplant analysis using flow cytometric techniques1 , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "47.19477"}
{"text": "IL-16-deficiency reduced graft inflammatory cell recruitment , and allograft inflammatory cytokine and chemokine production .Therefore , IL-16 neutralization may provide a potential target for novel therapeutic treatment for cardiac allograft rejection .", "label": "", "metadata": {}, "score": "47.207493"}
{"text": "In patients with a second treatment course , B - cells counts will be repeated on Day 72 \u00b1 7 .Patients in the verum group that continue to have more than five B - cells / \u03bcl in the peripheral blood will not receive further treatments with rituximab .", "label": "", "metadata": {}, "score": "47.256634"}
{"text": "The difference in the overall Banff classification of rejection between the groups was significant ( . by chi - square ) .Antibody - mediated rejection accounted for 4 % of the rejections in the SR group and 14 % in the CR group ( difference not significant ) .", "label": "", "metadata": {}, "score": "47.33814"}
{"text": "A recruitment period of three years is expected with 13 centers recruiting for the trial .Interventions and study plan .The diagnosis of an acute T - cell mediated tubulointerstitial rejection ( Banff IA / IB ) or a Banff borderline rejection with significant numbers of B - cells in the infiltrates is one of the major inclusion criteria for the RIACT study .", "label": "", "metadata": {}, "score": "47.352272"}
{"text": "Tracheal grafts in untreated recipients showed intense infiltration and complete luminal obliteration by day 28 .All 4 high - dose groups showed similar efficacy .", "label": "", "metadata": {}, "score": "47.567665"}
{"text": "Our aim was to determine among all of the anti - HLA antibodies , the effect of pre - transplant ( pre - Tx ) DSA in clinical outcome .", "label": "", "metadata": {}, "score": "47.57302"}
{"text": "Recruitment is complete , and follow - up will continue for around 5 years post - transplant .The primary endpoint for the induction therapy comparison is biopsy - proven acute rejection by 6 months , and the primary endpoint for the maintenance therapy comparison is change in estimated glomerular filtration rate from baseline to 2 years after transplantation .", "label": "", "metadata": {}, "score": "47.82336"}
{"text": "The primary endpoint for the induction therapy comparison is biopsy - proven acute rejection by 6 months , and the primary endpoint for the maintenance therapy comparison is change in estimated glomerular filtration rate from baseline to 2 years after transplantation .", "label": "", "metadata": {}, "score": "47.967438"}
{"text": "The primary endpoint for the induction therapy comparison is biopsy - proven acute rejection by 6 months , and the primary endpoint for the maintenance therapy comparison is change in estimated glomerular filtration rate from baseline to 2 years after transplantation .", "label": "", "metadata": {}, "score": "47.967438"}
{"text": "All patients will also receive prophylaxis for pneumocystis jirovecii pneumonia for six months after the anti - rejection treatment according to the local center schemes .", "label": "", "metadata": {}, "score": "48.10093"}
{"text": "Histological evaluation of cell fate further confirmed findings of the in vivo cell tracking and transcriptomic analysis .Collectively , these data suggest that BMMC therapy , in its present iteration , may be less efficacious than once thought .", "label": "", "metadata": {}, "score": "48.105766"}
{"text": "Although some patients may wish to withdraw prematurely from the trial , it is assumed that GFR - values one year after inclusion into the study - the primary endpoint of the study - can be obtained from all patients .", "label": "", "metadata": {}, "score": "48.22878"}
{"text": "This finding helps justify the inclusion of Banff borderline changes in the analysis of the impact of acute rejection on death - censored graft survival in this study of patients on an RSW immunosuppression protocol .", "label": "", "metadata": {}, "score": "48.268417"}
{"text": "We caution that the method of attributing the cause of graft failure is inherently subjective and there are currently no biomarkers available to identify the precise mechanism of graft failure .", "label": "", "metadata": {}, "score": "48.369"}
{"text": "This approach has translational potential for non - invasively assessing aneurysm tissue changes and risk , as well as monitoring elastin content in response to therapeutic interventions .", "label": "", "metadata": {}, "score": "48.462444"}
{"text": "PubMed View Article .Rush D , Nickerson P , Gough J , McKenna R , Grimm P , Cheang M , Trpkov K , Solez K , Jeffery J : Beneficial effects of treatment of early subclinical rejection : a randomized study .", "label": "", "metadata": {}, "score": "48.58828"}
{"text": "If a patient had both CR and SR on two separate biopsies , they were classified into the CR group .The cause of graft failure was determined by analyzing both clinical and pathology data .", "label": "", "metadata": {}, "score": "48.649864"}
{"text": "The Banff grade of rejection was higher in the CR group .There was a larger proportion of patients in both rejection groups with the combination of IFTA and persistent inflammation on the follow - up protocol biopsy done at 1 year .", "label": "", "metadata": {}, "score": "48.751358"}
{"text": "PubMed View Article .Hippen BE , DeMattos A , Cook WJ , Kew CE , Gaston RS : Association of CD20 + infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts .", "label": "", "metadata": {}, "score": "48.79602"}
{"text": "11 , pp .2561 - 2570 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Kanter Berga , A. Sancho Calabuig , E. Gavela Martinez et al . , \" Pretransplant donor - specific HLA antibodies detected by single antigen bead flow cytometry : risk factors and outcomes after kidney transplantation , \" Transplantation Proceedings , vol .", "label": "", "metadata": {}, "score": "48.838535"}
{"text": "IL-17 neutralization may provide a potential target for novel therapeutic treatment for cardiac allograft rejection .Abstract .In this study we systematically dissect the prenylation pathway to better define the mechanism behind statin inhibition in chronic allograft rejection in heart transplants , or transplant coronary artery disease ( TCAD ) .", "label": "", "metadata": {}, "score": "48.91637"}
{"text": "T cells contribute to acute allograft rejection thru interleukin ( IL)-17 production .Donor hearts from FVB mice ( H-2q ) were heterotopically transplanted into C57BL/6-wild type ( WT ) and ? ?", "label": "", "metadata": {}, "score": "48.964016"}
{"text": "The efficacy of Simulect for the prophylaxis of acute rejection in recipients of a second renal allograft has not been demonstrated .Long Term Follow - up .", "label": "", "metadata": {}, "score": "48.964233"}
{"text": "We treated mice with HLA - mismatched mouse cardiac transplant with atorvastatin and dasatinib and showed reduction of the CRM genes , significant reduction of graft - infiltrating cells , and extended graft survival .", "label": "", "metadata": {}, "score": "48.99456"}
{"text": "10.1056/NEJM199912023412303 .View Article .Meier - Kriesche HU , Schold JD , Kaplan B : Long - term renal allograft survival : have we made significant progress or is it time to rethink our analytic and therapeutic strategies ?", "label": "", "metadata": {}, "score": "49.127697"}
{"text": "Using meta - analysis of eight independent transplant datasets ( 236 graft biopsy samples ) from four organs , we identified a common rejection module ( CRM ) consisting of 11 genes that were significantly overexpressed in acute rejection ( AR ) across all transplanted organs .", "label": "", "metadata": {}, "score": "49.154625"}
{"text": "For example , graft failure and cancer ( with the possible exception of post - transplant lymphoproliferative disorder ) will be uncommon during the first few years after transplantation , when .", "label": "", "metadata": {}, "score": "49.233"}
{"text": "Even if renal allograft function returns to baseline values after anti - rejection therapy this may reflect some degree of compensatory hyperfiltration and obscure the loss of nephrons and development of interstitial fibrosis and tubular atrophy ( IF / TA ) [ 5 ] .", "label": "", "metadata": {}, "score": "49.263268"}
{"text": "In case that DSA not disappear in a reasonable period , desensitization protocols ( e.g. , plasma exchange and intravenous immunoglobulin ) could be necessary to transplant these patients and to avoid the almost sure nephrectomy .", "label": "", "metadata": {}, "score": "49.2704"}
{"text": "11 , pp .1681 - 1688 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Gupta , V. Iveson , M. Varagunam , S. Bodger , P. Sinnott , and R. C. Thuraisingham , \" Pretransplant donor - specific antibodies in cytotoxic negative crossmatch kidney transplants : are they relevant ? \" Transplantation , vol . 85 , no . 8 , pp .", "label": "", "metadata": {}, "score": "49.2806"}
{"text": "4 , pp .747 - 752 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. J. Matas , K. J. Gillingham , W. D. Payne , and J. S. Najarian , \" The impact of an acute rejection episode on long - term renal allograft survival ( t1/2 ) , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "49.408195"}
{"text": "The ? ?T cells promote acute cardiac allograft rejection , presumably by producing IL-17 .The ? ?T cell depletion may prove beneficial in prolonging allograft survival by suppressing IL-17 production .", "label": "", "metadata": {}, "score": "49.727146"}
{"text": "There were some differences in the treatment of rejection between the groups ( Table 5 ) .The difference in the overall categories of treatment between the groups was borderline significant ( .", "label": "", "metadata": {}, "score": "49.736153"}
{"text": "565 - 573 , 2000 .View at Google Scholar \u00b7 View at Scopus .R. Emiro\u01e7lu , M. C. Yagmurdur , F. Karakayali et al . , \" Role of donor age and acute rejection episodes on long - term graft survival in cadaveric kidney transplantations , \" Transplantation Proceedings , vol .", "label": "", "metadata": {}, "score": "49.82408"}
{"text": "Cytokine production was decreased in recipient spleens in all treatment groups .Both in vitro and in vivo IFN- ? -stimulated MHC II expression was decreased in a dose - dependent manner in the atorvastatin , perillyl alcohol and NE-10790 groups .", "label": "", "metadata": {}, "score": "50.06617"}
{"text": "The progression of interstitial fibrosis and tubular atrophy \u0394IF / TA between the biopsy that led to enrollment in the study and the biopsy one year after intervention will be quantified using specific staining und computerized image analysis .", "label": "", "metadata": {}, "score": "50.164455"}
{"text": "4 , pp .511 - 514 , 1995 .View at Google Scholar \u00b7 View at Scopus .R. J. Knight , L. Burrows , and C. Bodian , \" The influence of acute rejection on long - term renal allograft survival : a comparison of living and cadaveric donor transplantation , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "50.19139"}
{"text": "69 - 76 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Schreiber , S. Huls , R. Kuhn , and H. H. Neumayer , \" Causes of early graft failure at less than 12 months after renal transplantation , \" Transplantation Proceedings , vol .", "label": "", "metadata": {}, "score": "50.250694"}
{"text": "The correlation between the elevated serum creatinine levels at 12 months and graft survival has been documented in several studies [ 11 , 15 ] .", "label": "", "metadata": {}, "score": "50.329407"}
{"text": "Donor hearts transplanted into TCR ?-/- recipients had reduced IL-17 and IL-6 messenger RNA expression .Corroborating the gene expression , intracellular cytokine staining showed decreased IL-17 producing cells in TCR ?", "label": "", "metadata": {}, "score": "50.384342"}
{"text": "Moreover , transcriptomic analysis of BMMCs revealed nonspecific upregulation of various cell regulatory genes , with a marked downregulation of cell differentiation and maturation pathways .", "label": "", "metadata": {}, "score": "50.496815"}
{"text": "Discussion .Late graft failure is a major issue for kidney - transplant recipients .If our hypothesis that minimizing CNI exposure with Campath - based induction therapy and/or an elective conversion to sirolimus - based maintenance therapy can improve long - term graft function and survival is correct , then patients should experience better graft function for longer .", "label": "", "metadata": {}, "score": "50.588978"}
{"text": "In fact , these differences are due to HS patients with preformed DSA because only these recipients were significantly different from non - HS patients ( .", "label": "", "metadata": {}, "score": "50.613983"}
{"text": "In case the study is continued to the final analysis , the null hypothesis can be rejected if the P - value in the final analysis is less than 0.023 ( one - sided ) .", "label": "", "metadata": {}, "score": "50.62509"}
{"text": "Subanalyses will include the effect of rituximab in patients with different severity grades of rejection ( Borderline , Type I and II ) , different immunosupression before inclusion in the study and patient groups receiving one versus two applications of rituximab .", "label": "", "metadata": {}, "score": "50.64036"}
{"text": "This includes the small number of reported cases , short follow - up periods and heterogeneity of inclusion criteria , and the histological grading in these studies .", "label": "", "metadata": {}, "score": "50.75556"}
{"text": "In a small non - randomized pilot study of 12 patients , it appeared to be effective , but was associated with severe infective episodes [ 6 ] .", "label": "", "metadata": {}, "score": "50.82405"}
{"text": "11 , pp .1524 - 1528 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Gupta and P. Sinnott , \" Clinical relevance of pretransplant human leukocyte antigen donor - specific antibodies in renal patients waiting for a transplant : a risk factor , \" Human Immunology , vol .", "label": "", "metadata": {}, "score": "50.851833"}
{"text": "Transplantation .10.1097/TP.0b013e3181927a41 .View Article PubMed .Am J Transplant .10.1111/j.1600 - 6143.2009.02615.x .View Article PubMed .Budde K , Becker T , Arns W , Sommerer C , Reinke P , Eisenberger U , Kramer S , Fischer W , Gschaidmeier H , Pietruck F : Everolimus - based , calcineurin - inhibitor - free regimen in recipients of de - novo kidney transplants : an open - label , randomised , controlled trial .", "label": "", "metadata": {}, "score": "50.85267"}
{"text": "Early ( 6 \u00b1 3 days ) and late ( 2.9 \u00b1 1.7 , 1 - 10 years ) postoperative echocardiographic results were compared ( cumulative echocardiographic follow - up , 190 patient - years ; median late interval , 2 years [ interquartile range , 0.68 , 4.2 ] ) .", "label": "", "metadata": {}, "score": "50.88599"}
{"text": "View Article .Nankivell BJ , Borrows RJ , Fung CL , O'Connell PJ , Allen RD , Chapman JR : The natural history of chronic allograft nephropathy .", "label": "", "metadata": {}, "score": "50.941895"}
{"text": "Differences in classification between the investigators occurred in 26 % of the cases , and for these cases the cause was determined by consensus .Immunosuppression Protocol .", "label": "", "metadata": {}, "score": "50.975414"}
{"text": "At the time of rejection , the fraction of biopsies with an IFTA ( Banff ci plus ct ) greater than 2 was numerically higher in the SR group ( 43 % versus 24 % in the CR group ) but this difference was not statistically significant .", "label": "", "metadata": {}, "score": "51.026554"}
{"text": "However , the safety and efficacy of such strategies are unknown .Methods / Design .The Campath , Calcineurin inhibitor reduction and Chronic allograft nephropathy ( 3C ) Study is a multicentre , open - label , randomized controlled trial with 852 participants which is addressing two important questions in kidney transplantation .", "label": "", "metadata": {}, "score": "51.046955"}
{"text": "Page 18 . combined with deoxyspergualin .Transplantation .2005;Vol .[ Cross Ref ] [ PubMed ] 18 .Tan HP , Kaczorowski DJ , Basu A , Unruh M , McCauley J , Wu C , Donaldson J , Dvorchik I , Kayler L , Marcos A. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy .", "label": "", "metadata": {}, "score": "51.067345"}
{"text": "In heterotopic allografts , airway epithelium was rapidly destroyed and OAD progressed with complete luminal occlusion by 30 days .OAD developed with circular orientation of cells and connective tissue fibers to 45+/-6 % obliteration by day 60 .", "label": "", "metadata": {}, "score": "51.115536"}
{"text": "No 141/2000 ) \" and the \" Guideline on Clinical Trials in Small Populations ( CHMP / EWP/83561/2005 ) \" .The study protocol has been approved by the local ethics committees and national authorities .", "label": "", "metadata": {}, "score": "51.199825"}
{"text": "12 , pp .1864 - 1868 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Vaidya , D. Partlow , B. Susskind , M. Noor , T. Barnes , and K. Gugliuzza , \" Prediction of crossmatch outcome of highly sensitized patients by single and/or multiple antigen bead luminex assay , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "51.25368"}
{"text": "Nonetheless , this is a study on a large number of patients , with a long - term followup ( beyond ten years posttransplant ) and we could find interesting results .", "label": "", "metadata": {}, "score": "51.34938"}
{"text": "[ Cross Ref ] [ PubMed ] 28 .Matas AJ .Chronic progressive calcineurin nephrotoxicity : an overstated concept .Am J Transplant .2011;Vol .", "label": "", "metadata": {}, "score": "51.391014"}
{"text": "All immunosuppressive regimens according to local transplant center standards at the time of rejection diagnosis are acceptable , except previous use of rituximab to have the obtained results applicable to a broad patient population .", "label": "", "metadata": {}, "score": "51.394123"}
{"text": "Two double - blind , randomized , placebo - controlled studies ( Study 3 and Study 4 ) assessed the safety and efficacy of Simulect for the prophylaxis of acute renal transplant rejection in adults when used in combination with a triple immunosuppressive regimen .", "label": "", "metadata": {}, "score": "51.430893"}
{"text": "[ Cross Ref ] 4 .Nankivell BJ , Borrows RJ , Fung CL , O'Connell PJ , Allen RD , Chapman JR .The natural history of chronic allograft nephropathy .", "label": "", "metadata": {}, "score": "51.464806"}
{"text": "FACS results , that could give a hint which patient is in the verum respectively in the placebo group , will not be handed out to the study physician , but will be sent from the FACS facility to the unblinded randomization team in the Department of Biostatistics .", "label": "", "metadata": {}, "score": "51.508503"}
{"text": "IL-17(-/- ) recipient mice exhibited decreased IL-6 production and reciprocally enhanced regulatory T cell expansion , suggesting a contribution of regulatory T cells to prolonged allograft survival .", "label": "", "metadata": {}, "score": "51.518936"}
{"text": "1268 - 1272 , 1997 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . F. L. Luan , D. E. Steffick , C. Gadegbeku , S. P. Norman , R. Wolfe , and A. O. Ojo , \" Graft and patient survival in kidney transplant recipients selected for de novo steroid - free maintenance immunosuppression , \" American Journal of Transplantation , vol .", "label": "", "metadata": {}, "score": "51.521404"}
{"text": "PubMed View Article .Sarwal M , Chua MS , Kambham N , Hsieh SC , Satterwhite T , Masek M , Salvatierra O Jr : Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling .", "label": "", "metadata": {}, "score": "51.613365"}
{"text": "View Article PubMed .Bloom DD , Hu H , Fechner JH , Knechtle SJ : T - lymphocyte alloresponses of Campath-1H - treated kidney transplant patients .", "label": "", "metadata": {}, "score": "51.692978"}
{"text": "Kidney graft survival has been mainly evaluated using an up to 10-year threshold .Between groups comparisons were done using Mann - Whitney and chi - square test .", "label": "", "metadata": {}, "score": "51.751797"}
{"text": "Table 2 : Univariable study of risk factors of acute rejection in HS group .In order to improve this predictive value , we analyzed the characteristics of all data which could be implied in acute rejection .", "label": "", "metadata": {}, "score": "51.777508"}
{"text": "Study design .The RIACT - study is a randomized , double - blind , placebo - controlled , parallel group multicenter Phase III study .", "label": "", "metadata": {}, "score": "51.81685"}
{"text": "Zand MS : Rituximab in pediatric renal transplantation : a treatment for allograft rejection with B - cell infiltrates ?Am J Transplant 2008 , 8 : 2489 - 2490 .", "label": "", "metadata": {}, "score": "51.93605"}
{"text": "Five patients ( 5 % ) had moderate aortic regurgitation at 1 year , which did not progress subsequently .Further , we suggest that mild aortic regurgitation should not be considered nonstructural valve dysfunction , as the 2008 valve reporting guidelines would indicate .", "label": "", "metadata": {}, "score": "51.937294"}
{"text": "The incidence of AR and the death censored allograft one year survival was significantly different between non - HS group and the HS patients ( Table 1 ) .", "label": "", "metadata": {}, "score": "51.978043"}
{"text": "Discussion .Page 12 .Late graft loss ( that is , more than 1 year after transplantation ) is a major issue for kidney - transplant recipients .", "label": "", "metadata": {}, "score": "52.027058"}
{"text": "1607 - 1619 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. E. Leggat , A. O. Ojo , A. B. Leichtman et al . , \" Long - term renal allograft survival : prognostic implication of the timing of acute rejection episodes , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "52.04124"}
{"text": "References .R. A. Wolfe , V. B. Ashby , E. L. Milford et al . , \" Comparison of mortality in all patients on dialysis , patients on dialysis awaiting transplantation , and recipients of a first cadaveric transplant , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "52.04165"}
{"text": "Patients withdrawn due to adverse events .Long term patient follow up Patients will be followed up for graft and patient survival at 12 , 24 , and 36 months post - transplantation .", "label": "", "metadata": {}, "score": "52.174484"}
{"text": "Patients seropositive for human immunodeficiency virus .Patients with a current malignancy or a history of malignancy ( within the past 5 years ) , except basal or nonmetastatic squamous cell carcinoma of the skin that has been treated successfully .", "label": "", "metadata": {}, "score": "52.1881"}
{"text": "PubMed View Article .Lehnhardt A , Mengel M , Pape L , Ehrich JH , Offner G , Strehlau J : Nodular B - cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab .", "label": "", "metadata": {}, "score": "52.35361"}
{"text": "There were 35 1-year biopsies done in the SR group ( 76 % of the group ) and 19 biopsies done in the CR group ( 53 % of the group ) .", "label": "", "metadata": {}, "score": "52.36488"}
{"text": "High - resolution imaging techniques in the future may lead to the morphological assessment of aortic medial wall thickness in vivo becoming a reality which , in theory , could provide a more refined risk prognostication for acute aortic dissection .", "label": "", "metadata": {}, "score": "52.40441"}
{"text": "Endpoint definition .The primary endpoint of the induction therapy comparison will be biopsy - proven acute rejection during the first 6 months after transplantation .", "label": "", "metadata": {}, "score": "52.415676"}
{"text": "For this reason , many recent studies have focused on reducing exposure to CNIs , and these have generally shown that this strategy produces better medium - term outcomes ( for example , graft function at 1 year ) [ 5 ] .", "label": "", "metadata": {}, "score": "52.453804"}
{"text": "At this time , the primary endpoint renal allograft function change is determined , along with the secondary endpoints as safety parameters and degree of renal allograft fibrosis and tubular atrophy in a protocol biopsy .", "label": "", "metadata": {}, "score": "52.48144"}
{"text": "Endpoint definition The primary endpoint of the induction therapy comparison will be biopsy - proven acute rejection during the first 6 months after transplantation .The Banff classification definition ( including those of the various subtypes ) will be used .", "label": "", "metadata": {}, "score": "52.525627"}
{"text": "Beginning in 2004 , C4d staining was routinely done on the one - month biopsies , and beginning in 2006 , C4d was done on all biopsies .", "label": "", "metadata": {}, "score": "52.661526"}
{"text": "The 1-year graft survival rates are now more than 90 % , so there is considerable interest in strategies that can maximize the life span of renal transplants .", "label": "", "metadata": {}, "score": "52.68653"}
{"text": "Third , treatment of these patients with an anti - CD20 antibody ( rituximab ) improves the allograft outcome as reported in single case observations and in one small study .", "label": "", "metadata": {}, "score": "52.807384"}
{"text": "1106 - 1112 , 2001 .View at Google Scholar \u00b7 View at Scopus .R. Pei , J. H. Lee , N. J. Shih , M. Chen , and P. I. Terasaki , \" Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "52.826256"}
{"text": "The aim of our study was to analyze the characteristics and other variables that impact long - term kidney graft survival ( beyond 10 years after KT ) .", "label": "", "metadata": {}, "score": "52.848053"}
{"text": "This process may be halted by rituximab , as a single dose of rituximab at 375 mg / m 2 has been shown to induce a sustained reduction of B - cells in the peripheral blood but also in the kidney allograft in most patients within the first 35 days [ 17 ] .", "label": "", "metadata": {}, "score": "52.91923"}
{"text": "A total of 85 BAV patients ( 68 males , age 44 \u00b1 11 years ) underwent Tirone David - V V - SARR between 1997 and 2013 .", "label": "", "metadata": {}, "score": "52.950718"}
{"text": "At the latest echocardiographic follow - up ( 95 % complete ) , 202 patients ( 94.8 % ) had none or trace aortic regurgitation , 10 ( 4.7 % ) mild , 0 had moderate to severe , and 1 ( 0.5 % ) had severe aortic regurgitation .", "label": "", "metadata": {}, "score": "53.040565"}
{"text": "7 , no . 3 , pp .518 - 526 , 2007 .View at Google Scholar .F. G. Cosio , J. P. Grande , H. Wadei , T. S. Larson , M. D. Griffin , and M. D. Stegall , \" Predicting subsequent decline in kidney allograft function from early surveillance biopsies , \" American Journal of Transplantation , vol .", "label": "", "metadata": {}, "score": "53.05388"}
{"text": "753 - 760 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Einecke , M. Mengel , L. Hidalgo , K. Allanach , K. S. Famulski , and P. F. Halloran , \" The early course of kidney allograft rejection : defining the time when rejection begins , \" American Journal of Transplantation , vol .", "label": "", "metadata": {}, "score": "53.06935"}
{"text": "-/- recipients compared with WT controls .Graft infiltrating cells , including CD45 + , CD4 + , CD8 + , and Gr1 + cells were significantly decreased in TCR ?", "label": "", "metadata": {}, "score": "53.08676"}
{"text": "Original Primary Outcome Measures ICMJE ( submitted : January 2 , 2009 ) .Composite primary endpoint for noninferiority will be used for efficacy failure within 12 months of randomization : Death , graft failure , biopsy - proven acute rejection or loss to follow - up .", "label": "", "metadata": {}, "score": "53.10029"}
{"text": "PubMed .Schwarz A , Mengel M , Gwinner W , Radermacher J , Hiss M , Kreipe H , Haller H : Risk factors for chronic allograft nephropathy after renal transplantation : a protocol biopsy study .", "label": "", "metadata": {}, "score": "53.14826"}
{"text": "PubMed View Article .Alausa M , Almagro U , Siddiqi N , Zuiderweg R , Medipalli R , Hariharan S : Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab .", "label": "", "metadata": {}, "score": "53.169716"}
{"text": "Page 9 .Both randomizations use a minimization algorithm that ensures balance for recipient age , ethnicity , type of transplant , human leukocyte antigen mismatch , sensitization status ( and for maintenance randomization , allocated induction therapy ) .", "label": "", "metadata": {}, "score": "53.172535"}
{"text": "It is assumed that ANCOVA with adjustment will lead to an increase of the power in the final analyses .The type - I - error is set to 5 % ( two - sided ) and the power is set to 80 % .", "label": "", "metadata": {}, "score": "53.230724"}
{"text": "Methods / Design .The RIACT study is designed as a randomized , double - blind , placebo - controlled , parallel group multicenter Phase III study .", "label": "", "metadata": {}, "score": "53.46588"}
{"text": "We have previously shown that ascending aortic aneurysm formation in Marfan mice ( Fbn1(C1039G/+ ) ) is associated with decreased aortic wall elastogenesis and increased elastin breakdown .", "label": "", "metadata": {}, "score": "53.480385"}
{"text": "This technology is able to detect lower levels of alloantibody and to define them more accurately than the conventional complement - dependent cytotoxicity ( CDC ) assay [ 4 - 6 ] .", "label": "", "metadata": {}, "score": "53.549004"}
{"text": "6 , pp .1367 - 1374 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. S. Choi , M. J. Shin , S. J. Shin et al . , \" Clinical significance of an early protocol biopsy in living - donor renal transplantation : ten - year experience at a single center , \" American Journal of Transplantation , vol .", "label": "", "metadata": {}, "score": "53.592983"}
{"text": "The cause of this difference in survival is unknown .The data do not indicate an increase in malignancy- or infection - related mortality .In Study 2 , patient survival in the placebo group ( 90 % ) was the same compared to Simulect group ( 90 % ) .", "label": "", "metadata": {}, "score": "53.607048"}
{"text": "As short - term results have improved , more patients with ESRD are opting for a transplant and more are surviving with functioning grafts into the second and third decades posttransplant [ 4 , 5 ] .", "label": "", "metadata": {}, "score": "53.68598"}
{"text": "Accordingly , sufficient numbers of patients in the placebo group will be randomized in advance to receive a second round of placebo treatment .( For each patient in the placebo group it will be randomized in advance whether he will receive a second round of placebo treatment or not .", "label": "", "metadata": {}, "score": "53.74774"}
{"text": "In a more optimistic scenario it is assumed that an improvement of 2.5 ml / min can be achieved in the treatment group .In this scenario , 58 patients per treatment group would be necessary .", "label": "", "metadata": {}, "score": "53.798397"}
{"text": "View at Google Scholar \u00b7 View at Scopus . S. Hariharan , C. P. Johnson , B. A. Bresnahan , S. E. Taranto , M. J. McIntosh , and D. Stablein , \" Improved graft survival after renal transplantation in the United States , 1988 to 1996 , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "53.87906"}
{"text": "Zarkhin V , Li L , Kambham N , Sigdel T , Salvatierra O , Sarwal MM : A randomized , prospective trial of rituximab for acute rejection in pediatric renal transplantation .", "label": "", "metadata": {}, "score": "53.944466"}
{"text": "The acute rejection must be diagnosed between 6 weeks and 12 months after kidney transplantation .The baseline allograft creatinine clearance ( calculated by the abbreviated MDRD formula [ 20 ] ; before the rejection has to be over 25 ml / min .", "label": "", "metadata": {}, "score": "54.01857"}
{"text": "Traditionally , high panel reactive antibody ( PRA ) has been associated with increased immunologic risk and lower kidney graft survival [ 21 ] .As for HLA compatibility , it has been considered the most important independent factor for the 10-year survival rate of patients and the half - life of a patient 's first renal transplant .", "label": "", "metadata": {}, "score": "54.029255"}
{"text": "Follow BioMed Central .Trials main menu .Rationale and design of the RIACT - study : a multi - center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B - cell infiltrates in renal Transplant patients : study protocol for a randomized controlled trial .", "label": "", "metadata": {}, "score": "54.070908"}
{"text": "View Article PubMed .Calne R , Moffatt SD , Friend PJ , Jamieson NV , Bradley JA , Hale G , Firth J , Bradley J , Smith KG , Waldmann H : Prope tolerance with induction using Campath 1H and low - dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients .", "label": "", "metadata": {}, "score": "54.120506"}
{"text": "An interim analysis plan according to O'Brian and Flemming will be used [ 21 ] .The null hypothesis is that the change of the GFR is the same in patients treated with rituximab and under placebo .", "label": "", "metadata": {}, "score": "54.141327"}
{"text": "2003;Vol .[ Cross Ref ] .Page 17 .Ekberg H , Tedesco - Silva H , Demirbas A , Vitko S , Nashan B , Gurkan A , Margreiter R , Hugo C , Grinyo JM , Frei U. Reduced exposure to calcineurin inhibitors in renal transplantation .", "label": "", "metadata": {}, "score": "54.281525"}
{"text": "10.1056/NEJMoa020009 .View Article .Ekberg H , Tedesco - Silva H , Demirbas A , Vitko S , Nashan B , Gurkan A , Margreiter R , Hugo C , Grinyo JM , Frei U : Reduced exposure to calcineurin inhibitors in renal transplantation .", "label": "", "metadata": {}, "score": "54.286446"}
{"text": "Abstract .Different animal models have been developed to study the pathogenesis and treatment of obliterative airway disease ( OAD ) .Here we describe the techniques of heterotopic and orthotopic tracheal transplantations in the rat , comparing the kinetics of systemic host immune response and of histopathologic OAD development .", "label": "", "metadata": {}, "score": "54.31781"}
{"text": "Outcomes after transfemoral transcatheter aortic valve replacement : a comparison of the randomized PARTNER ( Placement of AoRTic TraNscathetER Valves ) trial with the NRCA ( Nonrandomized Continued Access ) registry .", "label": "", "metadata": {}, "score": "54.444916"}
{"text": "Trial registration ClinicalTrials.gov , NCT01120028 and ISRCTN88894088 Main article text Background Kidney transplantation is well established as the best treatment for patients with end- stage renal failure [ 1].", "label": "", "metadata": {}, "score": "54.46946"}
{"text": "In Study 4 , 123 patients were concomitantly treated with cyclosporine , USP ( MODIFIED ) , corticosteroids and mycophenolate mofetil ( MMF ) , of which 59 patients were treated with Simulect and 64 patients were treated with placebo .", "label": "", "metadata": {}, "score": "54.483536"}
{"text": "Infectious prophylaxis was also less effective , translating to higher incidence of CMV disease .Due to improvements related with these issues significant progress has been made in graft and patient survival rates after kidney transplant , since the 1980s [ 5 , 6 ] .", "label": "", "metadata": {}, "score": "54.510574"}
{"text": "2:1303[Cross Ref ] [ PubMed ] 23 .Bloom DD , Hu H , Fechner JH , Knechtle SJ .T - lymphocyte alloresponses of Campath-1H - treated kidney transplant patients .", "label": "", "metadata": {}, "score": "54.516743"}
{"text": "We show that metformin treatment activates AMP - activated kinase ( AMPK ) in vitro and in vivo .In the acute transplantation model , metformin activation of AMPK resulted in significantly decreased apoptosis in cardiac allografts on postoperative day ( POD ) 1 and 8 .", "label": "", "metadata": {}, "score": "54.622528"}
{"text": "Introduction .For patients with end - stage renal disease ( ESRD ) , a successful transplant ( compared with dialysis ) provides significantly higher survival rates and better quality of life [ 1 - 3 ] , which is directly linked to maintained function of the graft [ 4 ] .", "label": "", "metadata": {}, "score": "54.819675"}
{"text": "Cochrane Database Syst Rev 2006 , 2 : CD004756 .PubMed .Massy ZA , Guijarro C , Kasiske BL : Clinical predictors of chronic renal allograft rejection .", "label": "", "metadata": {}, "score": "54.834385"}
{"text": "Cells were characterized by flow cytometry and in vitro bioluminescence imaging ( BLI ) .Cell survival , proliferation , and migration were monitored by in vivo BLI , which was validated by ex vivo BLI , post - mortem immunohistochemistry , and flow cytometry .", "label": "", "metadata": {}, "score": "54.84854"}
{"text": "11 , pp .2532 - 2541 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. S. Gaston , B. Kaplan , T. Shah et al . , \" Fixed- or controlled - dose mycophenolate mofetil with standard- or reduced - dose calcineurin inhibitors : the opticept trial , \" American Journal of Transplantation , vol .", "label": "", "metadata": {}, "score": "54.866463"}
{"text": "At 25 centers , we randomly assigned 699 high - risk patients with severe aortic stenosis to undergo either surgical aortic - valve replacement or TAVR .", "label": "", "metadata": {}, "score": "54.98046"}
{"text": "Graft loss was defined as return to chronic dialysis , graft removal , a retransplant , or death .Delayed graft function was defined as the need for one or more dialysis treatments in the first posttransplant week .", "label": "", "metadata": {}, "score": "54.997074"}
{"text": "In vivo BLI revealed acute donor cell death of MSC , SkMb , and Fibro within 3 weeks after transplantation .Abstract .This study aimed to investigate the pharmacokinetics after tacrolimus aerosol inhalation and to assess its efficacy to suppress acute and chronic airway allograft rejection .", "label": "", "metadata": {}, "score": "55.049564"}
{"text": "15 , no . 9 - 10 , pp .508 - 514 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. O. Ojo , J. A. Hanson , R. A. Wolfe , A. B. Leichtman , L. Y. Agodoa , and F. K. Port , \" Long - term survival in renal transplant recipients with graft function , \" Kidney International , vol .", "label": "", "metadata": {}, "score": "55.08314"}
{"text": "483 - 493 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Vongwiwatana , A. Tasanarong , D. C. Rayner , A. Melk , and P. F. Halloran , \" Epithelial to mesenchymal transition during late deterioration of human kidney transplants : the role of tubular cells in fibrogenesis , \" American Journal of Transplantation , vol .", "label": "", "metadata": {}, "score": "55.08647"}
{"text": "All treatments will be used on an open - label basis .Monitoring .Before recruitment started , all sites were visited by the sponsor in order to train the relevant staff in the study procedures .", "label": "", "metadata": {}, "score": "55.139565"}
{"text": "Transplant Proc . 1995;Vol .[PubMed ] 7 .Huang E , Cho Y , Shah T , Peng A , Hayashi R , Bunnapradist S. Alemtuzumab induction in living donor kidney transplantation a multivariate analysis of the optn/ unos database .", "label": "", "metadata": {}, "score": "55.144573"}
{"text": "View at Google Scholar \u00b7 View at Scopus .P. Amico , G. H\u00f6nger , M. Mayr , J. Steiger , H. Hopfer , and S. Schaub , \" Clinical relevance of pretransplant donor - specific HLA antibodies detected by single - antigen flow - beads , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "55.15116"}
{"text": "We selected 23 HS patients out of 191 subjects transplanted in our Renal Transplant Unit between 2007 and 2008 and followed during 25 months ( median of followup 14 months , see Figure 1 ) .", "label": "", "metadata": {}, "score": "55.195713"}
{"text": "One interim analysis and one final analysis will be performed in this trial following the aforementioned decision rules ( see Sample size calculation ) .As soon as it can be demonstrated that rituximab is superior to placebo with respect to the primary endpoint , the secondary endpoint progression of interstitial fibrosis and tubular atrophy will be assessed in a confirmatory sense .", "label": "", "metadata": {}, "score": "55.2499"}
{"text": "Transplantation .tp.0000174341.49741.8f .View Article PubMed .Tan HP , Kaczorowski DJ , Basu A , Unruh M , McCauley J , Wu C , Donaldson J , Dvorchik I , Kayler L , Marcos A : Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy .", "label": "", "metadata": {}, "score": "55.359547"}
{"text": "10 , pp .2132 - 2143 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Opelz , \" Strength of HLA - A , HLA - B , and HLA - DR mismatches in relation to short- and long - term kidney graft survival .", "label": "", "metadata": {}, "score": "55.443916"}
{"text": "The discrimination for both scores was poor for 30-day / in - hospital and 1-year mortality .Calibration was better for STS score than for LES at 1 year but poor for both at 30 days among TAVR cohort .", "label": "", "metadata": {}, "score": "55.463074"}
{"text": "PubMed View Article .Tsai EW , Rianthavorn P , Gjertson DW , Wallace WD , Reed EF , Ettenger RB : CD20 + lymphocytes in renal allografts are associated with poor graft survival in pediatric patients .", "label": "", "metadata": {}, "score": "55.53191"}
{"text": "RESULTS :A multidisciplinary team ( anesthesia , hematology , cardiac surgery , and transfusion medicine ) was established to optimize perioperative hematologic management .Bleeding risk was assessed given the patient 's prior history and a dosing timeline for administration of blood products and recombinant clotting factors was established .", "label": "", "metadata": {}, "score": "55.53214"}
{"text": "Results .457 kidney transplant recipients treated with RSW were included ; 46 ( 10 % ) experienced SR , and 36 ( 7.8 % ) had CR .", "label": "", "metadata": {}, "score": "55.560005"}
{"text": "After obtaining their written informed consent , patients attend a screening visit .At this visit the patients are asked to provide a medical history ( with emphasis on the transplant history ) and undergo a physical examination .", "label": "", "metadata": {}, "score": "55.585762"}
{"text": "10.1111/j.1600 - 6143.2011.03637.x .View Article PubMed .Li Y , Zheng XX , Li XC , Zand MS , Strom TB : Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment .", "label": "", "metadata": {}, "score": "55.611767"}
{"text": "4 , pp .2614 - 2615 , 1993 .View at Google Scholar \u00b7 View at Scopus . H. Boom , M. J. K. Mallat , J. W. De Fijter , A. H. Zwinderman , and L. C. Paul , \" Delayed graft function influences renal function , but not survival , \" Kidney International , vol .", "label": "", "metadata": {}, "score": "55.612156"}
{"text": "PubMed .Seron D , Moreso F , Fulladosa X , Hueso M , Carrera M , Grinyo JM : Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies .", "label": "", "metadata": {}, "score": "55.661606"}
{"text": "The statistical analysis of the primary endpoint of the maintenance treatment will depend on the self - correlation of eGFR at baseline ( that is , at randomization into the maintenance comparison ) and at 2 years .", "label": "", "metadata": {}, "score": "55.762573"}
{"text": "Abstract .Baseline characteristics , procedural results , and 1-year outcomes were compared between patients undergoing TF - TAVR as part of the RCT and as part of the NRCA registry .", "label": "", "metadata": {}, "score": "55.95307"}
{"text": "Patients with reproductive potential who are unwilling / unable to use a double barrier method of contraception .Patients who were treated with any other investigational agent within 3 months before Screening .", "label": "", "metadata": {}, "score": "55.994453"}
{"text": "To assess the safety of the intervention , occurrence and frequency of adverse events in both treatment groups will be analyzed .These include the patient 's self - reported events and those inquired about by the study physician during regular study visits or obtained from additional in- and outpatient attendances .", "label": "", "metadata": {}, "score": "56.023907"}
{"text": "Transpl Int . 2006;Vol .[ Cross Ref ] [ PubMed ] 20 .Calne R , Moffatt SD , Friend PJ , Jamieson NV , Bradley JA , Hale G , Firth J , Bradley J , Smith KG , Waldmann H. Prope tolerance with induction using Campath 1H and low - dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients .", "label": "", "metadata": {}, "score": "56.101875"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00306397 Kidney transplantation is the best treatment for patients with end - stage renal failure , but uncertainty remains about the best immunosuppression strategy .", "label": "", "metadata": {}, "score": "56.123943"}
{"text": "In renal transplantation , donor age is known to have an important influence on the outcome of the graft reflecting functional renal mass [ 17 ] .", "label": "", "metadata": {}, "score": "56.131664"}
{"text": "Discussion .Late graft loss ( that is , more than 1 year after transplantation ) is a major issue for kidney - transplant recipients .", "label": "", "metadata": {}, "score": "56.138935"}
{"text": "Contraindication for a second transplant biopsy ( for example , coagulation disorders ) .Other reasons according to the assessments of the study physician .Sample size calculation .", "label": "", "metadata": {}, "score": "56.312637"}
{"text": "Abstract .Although interleukin-17 ( IL-17 ) has been reported to participate in the pathogenesis of infectious , autoimmune and allergic disorders , the precise role in allograft rejection remains uncertain .", "label": "", "metadata": {}, "score": "56.316483"}
{"text": "However , the current standard therapy for acute rejections focuses on T - cells .The RIACT study , therefore , tests the hypothesis that additional treatment of the rejection with rituximab is more efficacious than the standard treatment with steroid boli alone .", "label": "", "metadata": {}, "score": "56.44409"}
{"text": "An important and novel aspect of the 3C Study design is linkage with registries .Specific approval to flag all 3C Study participants with these registries has been obtained , and these will therefore provide a cost - efficient means of collecting data on all the relevant outcomes for the lifetime of the participant ( unless they withdraw consent ) .", "label": "", "metadata": {}, "score": "56.66414"}
{"text": "An important and novel aspect of the 3C Study design is linkage with registries .Specific approval to flag all 3C Study participants with these registries has been obtained , and these will therefore provide a cost - efficient means of collecting data on all the relevant outcomes for the lifetime of the participant ( unless they withdraw consent ) .", "label": "", "metadata": {}, "score": "56.66414"}
{"text": "Randomization and treatment scheme Participants will be randomized by an internet - based system before transplantation .After the participant is registered on the internet - based system , they are assigned a unique identifier ( participant ID ) , and once randomized , the assigned treatment group is displayed on the screen .", "label": "", "metadata": {}, "score": "56.7059"}
{"text": "The biopsy readings , including quantification of fibrosis , will be done without knowledge of the assignment to the treatment groups .All biopsies will be submitted to a second reading by a panel of renal pathologists .", "label": "", "metadata": {}, "score": "56.80289"}
{"text": "11 , pp .2410- 2419 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. M. Flechner , A. C. Novick , W. E. Braun , K. L. Popowniak , and D. Steinmuller , \" Functional capacity and rehabilitation of recipients with a functioning renal allograft for ten years or more , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "56.890697"}
{"text": "It was initially used de novo ( in conjunction with ciclosporin ) but is not as effective as CNIs during the high - risk post - operative period , and the doses required to prevent rejection ( including a high loading dose ) were associated with unacceptable adverse effects [ 10 ] .", "label": "", "metadata": {}, "score": "56.946404"}
{"text": "tp.0000191940.13473.59 .View Article PubMed .Gallon L , Gagliardini E , Benigni A , Kaufman D , Waheed A , Noris M , Remuzzi G : Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab ( Campath-1H ) .", "label": "", "metadata": {}, "score": "57.02208"}
{"text": "1501 - 1508 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .V. B. Ashby , F. K. Port , R. A. Wolfe et al . , \" Transplanting kidneys without points for HLA - B matching : consequences of the policy change , \" American Journal of Transplantation , vol .", "label": "", "metadata": {}, "score": "57.090706"}
{"text": "Secondary endpoints of the induction - therapy comparison will be analyzed in an exploratory manner , as there is a potential for bias in endpoints that occur after the maintenance - therapy randomization ( if inclusion in the maintenance - therapy comparison is not balanced between the two induction - therapy groups ) .", "label": "", "metadata": {}, "score": "57.10531"}
{"text": "Study assessments .The GFR of the renal allograft is the ultimate parameter that describes acute and chronic aspects of the graft function and is the most widely used measure for the outcome in renal transplantation studies .", "label": "", "metadata": {}, "score": "57.105797"}
{"text": "N Eng J Med . 1999;Vol .[ Cross Ref ] 2 .Meier - Kriesche HU , Schold JD , Kaplan B. Long - term renal allograft survival : have we made significant progress or is it time to rethink our analytic and therapeutic strategies ?", "label": "", "metadata": {}, "score": "57.171124"}
{"text": "Fluorescence activated cell sorting .GCP : .Good clinical practice .GFR : .Glomerular filtration rate .IF / TA : .Interstitial fibrosis and tubular atrophy .", "label": "", "metadata": {}, "score": "57.173676"}
{"text": "2000;Vol .[PubMed ] 21 .J Immunol . 2006;Vol .[PubMed ] 22 .Wells AD , Li XC .Requirement for T - cell apoptosis in the induction of peripheral transplantation tolerance .", "label": "", "metadata": {}, "score": "57.20031"}
{"text": "Six patients sustained acute type B aortic dissection ( freedom at 10 years , 90.4 % \u00b1 5.0 % ) .Tirone David reimplantation valve - sparing aortic root replacement in carefully selected young patients was associated with excellent clinical and echocardiographic outcome in patients with either a tricuspid aortic valve or bicuspid aortic valve .", "label": "", "metadata": {}, "score": "57.217903"}
{"text": "most studies cease follow - up .However , the 3C Study will continue follow - up for many more years , and therefore will accrue substantially more events and thus allow more reliable conclusions to be drawn .", "label": "", "metadata": {}, "score": "57.406643"}
{"text": "22 , no .4 , pp .818 - 824 , 2011 .View at Google Scholar .S. Prommool , G. S. Jhangri , S. M. Cockfield , and P. F. Halloran , \" Time dependency of factors affecting renal allograft survival , \" Journal of the American Society of Nephrology , vol .", "label": "", "metadata": {}, "score": "57.45869"}
{"text": "Aortic wall thickness : an independent risk factor for aortic dissection ? journal of heart valve disease Shiran , H. , Odegaard , J. , Berry , G. , Miller , D. C. , Fischbein , M. , Liang , D. 2014 ; 23 ( 1 ) : 17 - 24 .", "label": "", "metadata": {}, "score": "57.491196"}
{"text": "Intention - to - treat population .RIACT - study : .RItuximab in Acute Cellular tubulointerstitial rejection with B - cell infiltrates in renal Transplant patients .", "label": "", "metadata": {}, "score": "57.534477"}
{"text": "tp.0000237101.58974.43 .View Article PubMed .Yusuf S , Peto R , Lewis J , Collins R , Sleight P : Beta blockade during and after myocardial infarction : an overview of the randomized trials .", "label": "", "metadata": {}, "score": "57.597298"}
{"text": "2012;Vol .[ Cross Ref ] [ PubMed ] 9 .Hanaway MJ , Woodle ES , Mulgaonkar S , Peddi VR , Kaufman DB , First MR , Croy R , Holman J. Alemtuzumab induction in renal transplantation .", "label": "", "metadata": {}, "score": "57.67756"}
{"text": "The rationale for choosing 30 CD20 + cells /per hpf ( X400 ) in our trial is based on the observations of our pilot study , which was also used for assessment of graft outcome and sample size calculation .", "label": "", "metadata": {}, "score": "57.75081"}
{"text": "The regimen of Simulect was chosen to provide 30 - 45 days of IL-2R\u03b1 saturation .729 patients were enrolled in the two studies using a dual maintenance immunosuppressive regimen comprised of cyclosporine , USP ( MODIFIED ) and corticosteroids , of which 363 patients were treated with Simulect and 358 patients were placebo - treated .", "label": "", "metadata": {}, "score": "57.78742"}
{"text": "In addition , more controlled studies of the benefits of treating subclinical rejection are needed .K. Solez , R. B. Colvin , L. C. Racusen et al . , \" Banff 07 classification of renal allograft pathology : updates and future directions , \" American Journal of Transplantation , vol . 8 , no .", "label": "", "metadata": {}, "score": "57.798462"}
{"text": "Authors ' original submitted files for images .Below are the links to the authors ' original submitted files for images .Competing interests .The 3C Study has received funding from Pfizer and Novartis and a NHS Blood and Transplant Research and Development grant .", "label": "", "metadata": {}, "score": "57.830757"}
{"text": "CNI exposure could be minimized by using more potent induction therapy or alternative maintenance therapy to remove CNIs completely .However , the safety and efficacy of such strategies are unknown .", "label": "", "metadata": {}, "score": "57.8527"}
{"text": "CNI exposure could be minimized by using more potent induction therapy or alternative maintenance therapy to remove CNIs completely .However , the safety and efficacy of such strategies are unknown .", "label": "", "metadata": {}, "score": "57.8527"}
{"text": "Both SR and CR are associated with an inferior graft survival in recipients on RSW .Introduction .The process of allorecognition and acute rejection is an important mechanism of kidney allograft damage resulting in interstitial fibrosis and tubular atrophy ( IFTA ) .", "label": "", "metadata": {}, "score": "57.85623"}
{"text": "Noris M , Casiraghi F , Todeschini M , Cravedi P , Cugini D , Monteferrante G , Aiello S , Cassis L , Gotti E , Gaspari F : Regulatory T cells and T cell depletion : role of immunosuppressive drugs .", "label": "", "metadata": {}, "score": "57.869328"}
{"text": "Background .Kidney transplantation is well established as the best treatment for patients with end - stage renal failure [ 1 ] .Despite significant advances in short - term graft survival over the past two decades , these have not been matched by improved long - term graft survival [ 2 ] .", "label": "", "metadata": {}, "score": "57.979195"}
{"text": "Histological evidence of decreased and fragmented elastin was observed exclusively in the Fbn1(C1039G/+ ) ascending aorta in association with repressed elastin mRNA and increased matrix metalloproteinase-2 expression and activity , both targets of miR-29b .", "label": "", "metadata": {}, "score": "57.99063"}
{"text": "All patients received induction .Numerically , more patients received basiliximab induction in the CR and SR groups but this was not statistically significant .Only 3 patients received induction with alemtuzumab and the balance received r - ATG induction .", "label": "", "metadata": {}, "score": "57.995262"}
{"text": "Participants will be randomly allocated to receive either Campath - based or basiliximab - based induction therapy before transplantation .All participants will then receive 6 months of tacrolimus - based maintenance therapy before being randomized again ( if they remain willing and eligible ) to either sirolimus - based or tacrolimus - based long - term maintenance therapy ( Figure 1 ) .", "label": "", "metadata": {}, "score": "57.99539"}
{"text": "On a yearly basis , all participants will be sent an annual questionnaire to collect information on serious adverse events , study treatments , healthcare usage , and quality of life .", "label": "", "metadata": {}, "score": "58.00824"}
{"text": "On a yearly basis , all participants will be sent an annual questionnaire to collect information on serious adverse events , study treatments , healthcare usage , and quality of life .", "label": "", "metadata": {}, "score": "58.00824"}
{"text": "For the remaining 457 patients , 46 ( 10 % ) were classified as SR including Banff borderline changes in 18 and acute rejection in 25 .", "label": "", "metadata": {}, "score": "58.022583"}
{"text": "All participants will then receive 6 months of tacrolimus - based maintenance therapy before being randomized again ( if they remain willing and eligible ) to either sirolimus - based or tacrolimus- based long - term maintenance therapy ( Figure 1 ) .", "label": "", "metadata": {}, "score": "58.025867"}
{"text": "As a second endpoint , interstitial fibrosis and tubular atrophy ( IF / TA ) will be used as an indicator of established chronic damage .", "label": "", "metadata": {}, "score": "58.032288"}
{"text": "69 - 76 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus Different Impact of Pretransplant Anti - HLA Antibodies Detected by Luminex in Highly Sensitized Renal Transplanted Patients .", "label": "", "metadata": {}, "score": "58.05107"}
{"text": "852 participants have been randomized into the study ( of whom 355 have been re - randomized into the maintenance comparison at the time of submission ) .", "label": "", "metadata": {}, "score": "58.06225"}
{"text": "852 participants have been randomized into the study ( of whom 355 have been re - randomized into the maintenance comparison at the time of submission ) .", "label": "", "metadata": {}, "score": "58.06225"}
{"text": "Inclusion and exclusion criteria .The population of renal allograft recipients is heterogeneous ( for example , age , gender , first or repeated transplant , immunological risk ) , yet , all patients are at risk for acute rejection .", "label": "", "metadata": {}, "score": "58.074593"}
{"text": "In conclusion , we identified a CRM in transplantation that provides new opportunities for diagnosis , drug repositioning , and rational drug design .Abstract .", "label": "", "metadata": {}, "score": "58.082577"}
{"text": "The median number days from the index biopsy to the followup 1-year biopsy was 223 days for the SR group and 336 days for the CR group ( . )", "label": "", "metadata": {}, "score": "58.148483"}
{"text": "These aspects are considered in the design of the RIACT - study .The acronym RIACT - study stands for a multi - center randomized placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B - cell infiltrates in renal Transplant patients ( RIACT ) .", "label": "", "metadata": {}, "score": "58.2017"}
{"text": "At 30 days , death , cardiac death , stroke , and transient ischemic attacks were not different in the NRCA registry than in the RCT .", "label": "", "metadata": {}, "score": "58.289776"}
{"text": "Whereas CDC crossmatch positivity is an absolute contraindication to kidney transplantation , the clinical relevance of DSA detected by Luminex technology in patients with CDC crossmatch negative remains today unclear .", "label": "", "metadata": {}, "score": "58.340836"}
{"text": "We also thank the staff at each of the sites who have recruited and cared for the trial participants .The most important acknowledgement is to the participants in the 3C Study .", "label": "", "metadata": {}, "score": "58.44727"}
{"text": "Measures that address these issues ( careful donor selection , preemptive KT , and effective immunosuppressive protocols ) are still warranted .Conflict of Interests .", "label": "", "metadata": {}, "score": "58.504032"}
{"text": "The recruitment of 180 eligible patients will be challenging despite the multi - centric approach with 13 participating centers .Should the recruitment rate prove to be lower than expected in the first six months after the study begins , more centers will be asked to participate .", "label": "", "metadata": {}, "score": "58.59514"}
{"text": "Posttransplant protocol biopsies were done at months 1 , 4 and annually .Biopsies were performed in the outpatient radiology department with real - time ultrasound guidance using an 18 g BioPince biopsy gun to obtain at least one core .", "label": "", "metadata": {}, "score": "58.65657"}
{"text": "SR : subclinical rejection , CR : clinical rejection , AMR : antibody - mediated acute rejection , Bord : borderline change by Banff criteria .", "label": "", "metadata": {}, "score": "58.753372"}
{"text": "Finally , miR-29b blockade by locked nucleic acid antisense oligonucleotides prevented early aneurysm development , aortic wall apoptosis , and extracellular matrix deficiencies .We identify increased miR-29b expression as key to the pathogenesis of early aneurysm development in MFS by regulating aortic wall apoptosis and extracellular matrix abnormalities .", "label": "", "metadata": {}, "score": "58.79928"}
{"text": "Late graft failure is a major issue for kidney - transplant recipients .If our hypothesis that minimizing CNI exposure with Campath - based induction therapy and/or an elective conversion to sirolimus - based maintenance therapy can improve long - term graft function and survival is correct , then patients should experience better graft function for longer .", "label": "", "metadata": {}, "score": "58.817364"}
{"text": "Efficacy : .Primary endpoint .Plasma creatinine ( and creatinine clearance ( Cockcroft ) )Secondary endpoints .Incidence of first acute rejections and total number of acute rejections .", "label": "", "metadata": {}, "score": "58.84152"}
{"text": "Transplantation . 2006;Vol .[ Cross Ref ] [ PubMed ] 27 .Yusuf S , Peto R , Lewis J , Collins R , Sleight P. Beta blockade during and after myocardial infarction : an overview of the randomized trials .", "label": "", "metadata": {}, "score": "58.845936"}
{"text": "Abstract .The logistic European System for Cardiac Operative Risk Evaluation ( LES ) score and the Society of Thoracic Surgeons ( STS ) score are validated to predict 30-day outcomes following surgical aortic valve replacement ( SAVR ) with or without coronary artery bypass grafting .", "label": "", "metadata": {}, "score": "58.899155"}
{"text": "6 , pp .857 - 859 , 1994 .View at Google Scholar \u00b7 View at Scopus .B. J. Nankivell , R. J. Borrows , C. L. Fung , P. J. O'Connell , R. D. Allen , and J. R. Chapman , \" Natural history , risk factors , and impact of subclinical rejection in kidney transplantation , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "58.90564"}
{"text": "2(1 Suppl 2):375 - 376 .[PubMed ] 8 .Morgan RD , O'Callaghan JM , Knight SR , Morris PJ .Alemtuzumab induction therapy in kidney transplantation : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "58.95264"}
{"text": "43 - 49 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. M. Gebel , O. Moussa , D. D. Eckels , and R. A. Bray , \" Donor - reactive HLA antibodies in renal allograft recipients : considerations , complications , and conundrums , \" Human Immunology , vol .", "label": "", "metadata": {}, "score": "58.995934"}
{"text": "Abstract .The main cause of mortality after the first year from cardiac transplantation is cardiac allograft vasculopathy ( CAV ) , which leads to chronic rejection of the heart .", "label": "", "metadata": {}, "score": "58.99717"}
{"text": "Sample size .The sample size for the 3C Study was determined by the maintenance therapy allocation .A meta - analysis of the effect of conversion to sirolimus - based maintenance therapy showed an improvement in eGFR of 6.4 ml / min/1.73 m 2 ( 95 % CI 1.9 to 11 ) in the group assigned to sirolimus [ 26 ] .", "label": "", "metadata": {}, "score": "59.026398"}
{"text": "Clinical outcome and valve function were analyzed using log - rank calculations .Actuarial survival was 99 % \u00b1 2 % ; freedom from reoperation was 90 % \u00b1 5 % , infection 98 % \u00b1 2 % , and stroke 100 % at 6 years .", "label": "", "metadata": {}, "score": "59.05847"}
{"text": "Statistical Analysis .Comparison of the characteristics between the groups ( CR , SR , no rejection group ) was done using ANOVA and Student 's .", "label": "", "metadata": {}, "score": "59.07344"}
{"text": "Figure 1 : Distribution of Banff classification of acute rejection .Banff borderline changes were included with the rejection groups .The SR group had milder grades of acute cellular rejection compared to the CR group ( . by chi - square ) .", "label": "", "metadata": {}, "score": "59.102985"}
{"text": "610 - 617 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Lefaucheur , C. Suberbielle - Boissel , G. S. Hill et al . , \" Clinical relevance of preformed HLA donor - specific antibodies in kidney transplantation , \" Contributions to Nephrology , vol .", "label": "", "metadata": {}, "score": "59.205322"}
{"text": "CAV was associated with decreased donor organ inflammation , as well as donor organ cytokine ( IL-1 ? and IL-6 ) and chemokine ( MCP-1 and KC ) protein expression .", "label": "", "metadata": {}, "score": "59.21862"}
{"text": "PubMed .J Immunol .View Article PubMed .Wells AD , Li XC : Requirement for T - cell apoptosis in the induction of peripheral transplantation tolerance .", "label": "", "metadata": {}, "score": "59.317856"}
{"text": "Ischemia - reperfusion ( I - R ) injury has been shown to be the strongest alloantigen - independent factor in the development of CAV .", "label": "", "metadata": {}, "score": "59.358788"}
{"text": "10.2215/CJN.01741105 .View Article PubMed .Levey AS , Bosch JP , Lewis JB , Greene T , Rogers N , Roth D : A more accurate method to estimate glomerular filtration rate from serum creatinine : a new prediction equation .", "label": "", "metadata": {}, "score": "59.468334"}
{"text": "6 , pp .572 - 576 , 1983 .View at Google Scholar \u00b7 View at Scopus . A. E. El - Agroudy , K. El - Dahshan , T. M. Abbass , A. M. Ismail , A. A. Shokeir , and M. A. Ghoneim , \" Characteristics of recipients whose kidney allograft has functioned for more than 20 years , \" Experimental and Clinical Transplantation , vol .", "label": "", "metadata": {}, "score": "59.489204"}
{"text": "The authors thank Antonia Rodriguez de la Pe\u00f1a for expert technical assistance and Cristina Fernandez for her help in statistical analysis .References . H. U. Meier - Kriesche , A. O. Ojo , J. A. Hanson et al . , \" Increased impact of acute rejection on chronic allograft failure in recent era , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "59.5044"}
{"text": "It is well know that anti - HLA antibodies are an important obstacle in kidney transplantation .Our aim was to study the clinical impact of pretransplant donor specific anti - HLA antibodies ( HLA - DSA ) , in highly sensitized ( HS ) patients .", "label": "", "metadata": {}, "score": "59.50608"}
{"text": "Sample size The sample size for the 3C Study was determined by the maintenance therapy allocation .A meta - analysis of the effect of conversion to sirolimus - based maintenance therapy showed an improvement in eGFR of 6.4 ml / min/1.73m2 ( 95 % CI 1.9 to 11 ) in the group assigned to sirolimus [ 26].", "label": "", "metadata": {}, "score": "59.51214"}
{"text": "Using broader exclusion criteria and conducting a small number of carefully pre - specified subgroup analyses will provide reliable information about whether any effect of either strategy is modified by certain baseline characteristics .", "label": "", "metadata": {}, "score": "59.53354"}
{"text": "Using broader exclusion criteria and conducting a small number of carefully pre - specified subgroup analyses will provide reliable information about whether any effect of either strategy is modified by certain baseline characteristics .", "label": "", "metadata": {}, "score": "59.53354"}
{"text": "2006;Vol .[ Cross Ref ] [ PubMed ] 25 .Levey AS , Bosch JP , Lewis JB , Greene T , Rogers N , Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine : a new prediction equation .", "label": "", "metadata": {}, "score": "59.548515"}
{"text": "The first question is whether a Campath ( alemtuzumab)-based induction therapy strategy is superior to basiliximab - based therapy , and the second is whether , from 6 months after transplantation , a sirolimus - based maintenance therapy strategy is superior to tacrolimus - based therapy .", "label": "", "metadata": {}, "score": "59.56363"}
{"text": "The first question is whether a Campath ( alemtuzumab)-based induction therapy strategy is superior to basiliximab - based therapy , and the second is whether , from 6 months after transplantation , a sirolimus - based maintenance therapy strategy is superior to tacrolimus - based therapy .", "label": "", "metadata": {}, "score": "59.56363"}
{"text": "155 - 160 , 2008 .View at Google Scholar \u00b7 View at Scopus .P. I. Terasaki , J. D. McClelland , J. Yuge et al . , \" Advances in kidney transplantation : 1985 - 1995 , \" Clinical Transplants , pp .", "label": "", "metadata": {}, "score": "59.56531"}
{"text": "Table 1 summarizes the results of these studies .Figure 1 displays the Kaplan - Meier estimates of the percentage of patients by treatment group experiencing the primary efficacy endpoint during the first 12 months post - transplantation for Study 2 .", "label": "", "metadata": {}, "score": "59.58596"}
{"text": "PubMed .Huang E , Cho Y , Shah T , Peng A , Hayashi R , Bunnapradist S : Alemtuzumab induction in living donor kidney transplantation a multivariate analysis of the optn/ unos database .", "label": "", "metadata": {}, "score": "59.62159"}
{"text": "TRANSPLANTATION PROCEEDINGS Deuse , T. , Schrepfer , S. , Pelletier , M. P. , Fischbein , M. P. , Robbins , R. C. , Reichenspurner , H. 2007 ; 39 ( 2 ) : 569 - 572 .", "label": "", "metadata": {}, "score": "59.684074"}
{"text": "Results .Global Population .The majority of the enrolled patients were men ( 59.4 % ) , with median age 37.0 years [ IQR 27.6 - 47.1 ] at the time of transplant .", "label": "", "metadata": {}, "score": "59.89683"}
{"text": "[ Cross Ref ] [ PubMed ] 24 .Gallon L , Gagliardini E , Benigni A , Kaufman D , Waheed A , Noris M , Remuzzi G. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab ( Campath-1H ) .", "label": "", "metadata": {}, "score": "59.91358"}
{"text": "The determination of anti HLA class II antibodies was carried out by Lifecodes Class II ID , which is a Luminex assay for detection of IgG panel reactive antibodies to HLA class II molecules .", "label": "", "metadata": {}, "score": "59.913883"}
{"text": "Surprisingly , we found that gamma delta T cells rather than CD4(+ ) and CD8(+ ) T cells were key IL-17 producers in the allografts .", "label": "", "metadata": {}, "score": "60.00769"}
{"text": "CASE REPORT : A 59-year - old male with Type I GT and a history of transfusion reactions to PLT infusions developed severe aortic stenosis secondary to bicuspid valve disease .", "label": "", "metadata": {}, "score": "60.052544"}
{"text": "Abbreviations .3C Study : .Campath Calcineurin inhibitor reduction and Chronic allograft nephropathy .CNI : .Calcineurin inhibitor .eGFR : .Estimated glomerular filtration rate .", "label": "", "metadata": {}, "score": "60.05682"}
{"text": "Recently , Woodle et al . reported the results of a 5-year multicenter , randomized trial of early steroid withdrawal [ 13 ] .", "label": "", "metadata": {}, "score": "60.133812"}
{"text": "Results of open surgical repair of descending and thoracoabdominal aortic aneurysms have improved dramatically over the years .Nevertheless , while adjunctive protective strategies , such as spinal cord drainage and distal aortic perfusion , have improved outcomes , clinical challenges remain .", "label": "", "metadata": {}, "score": "60.272522"}
{"text": "10.1056/NEJMoa1009546 .View Article .Flechner SM : Reviewing the evidence for de novo immunosuppression with sirolimus .Transplant Proc .2008 , 40 ( 10 Suppl ) : S25-S28 .", "label": "", "metadata": {}, "score": "60.324894"}
{"text": "PubMed View Article .Mengel M , Gwinner W , Schwarz A , Bajeski R , Franz I , Br\u00f6cker V , Becker T , Neipp M , Klempnauer J , Haller H , Kreipe H : Infiltrates in protocol biopsies from renal allografts .", "label": "", "metadata": {}, "score": "60.390842"}
{"text": "Genberg H , Hansson A , Wernerson A , Wennberg L , Tyden G : Pharmacodynamics of rituximab in kidney transplantation .Transplantation 2007 , 84 : S33-S36 .", "label": "", "metadata": {}, "score": "60.40917"}
{"text": "The commonest reason for such late graft failure is IF / TA .Data from serial protocol biopsies previously suggested that CNI nephrotoxicity was an important cause of IF / TA [ 4 ] , although this has been debated more recently [ 28,29].", "label": "", "metadata": {}, "score": "60.41704"}
{"text": "The commonest reason for such late graft failure is IF / TA .Data from serial protocol biopsies previously suggested that CNI nephrotoxicity was an important cause of IF / TA [ 4 ] , although this has been debated more recently [ 28 , 29 ] .", "label": "", "metadata": {}, "score": "60.41704"}
{"text": "The benefits appear to be durable in the medium term [ 14 ] , but whether these translate into differences in clinical outcomes such as graft failure remains uncertain .", "label": "", "metadata": {}, "score": "60.419315"}
{"text": "B , a repressor of miR-29b , and a factor suppressed by TGF- ? , was also observed in Fbn1(C1039G/+ ) aorta .Furthermore , administration of a nuclear factor ?", "label": "", "metadata": {}, "score": "60.423447"}
{"text": "Therefore , improving the long - term survival of KT by identifying modifiable risk factors is an important subject in the field of organ transplantation .", "label": "", "metadata": {}, "score": "60.436787"}
{"text": "Most donors were also men ( 70.9 % ) .Median posttransplant follow - up time was 176.2 months [ IQR 138.2 - 222.4].", "label": "", "metadata": {}, "score": "60.471672"}
{"text": "Study objectives To obtain preliminary information on the efficacy and safety of a rapamycin / sodium - mycophenolate ( Myfortic ) / tacrolimus regimen in the absence of steroids for the prevention of acute rejection following renal transplantation .", "label": "", "metadata": {}, "score": "60.481705"}
{"text": "The 3C Study deliberately includes a wide range of kidney - transplant recipients .as all transplants are vulnerable to the nephrotoxic effects of CNIs , and it is important to ensure that the results will be applicable to as many kidney - transplant recipients as possible .", "label": "", "metadata": {}, "score": "60.70205"}
{"text": "The 3C Study deliberately includes a wide range of kidney - transplant recipients .as all transplants are vulnerable to the nephrotoxic effects of CNIs , and it is important to ensure that the results will be applicable to as many kidney - transplant recipients as possible .", "label": "", "metadata": {}, "score": "60.70205"}
{"text": "( Funded by Edwards Lifesciences ; ClinicalTrials.gov number , NCT00530894 . )Abstract .This study aims to provide insight into cellular kinetics using molecular imaging after different transplantation methods of bone marrow - derived mononuclear cells ( MNCs ) in a mouse model of peripheral artery disease ( PAD ) .", "label": "", "metadata": {}, "score": "60.73604"}
{"text": "PubMed View Article .Martin F , Chan AC : B cell immunobiology in disease : evolving concepts from the clinic .Annu Rev Immunol 2006 , 24 : 467 - 496 .", "label": "", "metadata": {}, "score": "60.77732"}
{"text": "1098 - 1100 , 2000 .View at Google Scholar \u00b7 View at Scopus . H. U. Meier - Kriesche and B. Kaplan , \" Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes : a paired donor kidney analysis , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "60.789185"}
{"text": "307 - 313 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .O. J. Kwon , J. Y. Kwak , and C. M. Kang , \" The impact of gender and age matching for long - term graft survival in living donor renal transplantation , \" Transplantation Proceedings , vol .", "label": "", "metadata": {}, "score": "60.7966"}
{"text": "2006 , 82 ( 1 Suppl 2 ) : 375 - 376 .Morgan RD , O'Callaghan JM , Knight SR , Morris PJ : Alemtuzumab induction therapy in kidney transplantation : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "60.91004"}
{"text": "IF / TA is believed to be the end result of various types of graft damage , including preservation damage , rejection , calcineurin inhibitor ( CNI ) toxicity , hypertensive vascular disease , and viral infection .", "label": "", "metadata": {}, "score": "60.964302"}
{"text": "However , with its antiproliferative effects on smooth muscle cells , its good tolerability , and its blockade of cytomegalovirus replication , FK778 proved effective to prevent chronic OAD development .", "label": "", "metadata": {}, "score": "61.02778"}
{"text": "1712 - 1718 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. A. Schnitzler , R. S. Woodward , D. C. Brennan , E. L. Spitznagel , W. C. Dunagan , and T. C. Bailey , \" Impact of cytomegalovirus serology on graft survival in living related kidney transplantation : implications for donor selection , \" Surgery , vol .", "label": "", "metadata": {}, "score": "61.097015"}
{"text": "Enrolled population characteristics are presented in Table 1 .Discussion .This study focused only on patients with more than 10 years of followup , referring to kidney transplant performed between the year of 1983 and 2000 .", "label": "", "metadata": {}, "score": "61.183304"}
{"text": "5 , pp .S621-S624 , 1992 .View at Google Scholar \u00b7 View at Scopus .X. Su , S. A. Zenios , H. Chakkera , E. L. Milford , and G. M. Chertow , \" Diminishing significance of HLA matching in kidney transplantation , \" American Journal of Transplantation , vol .", "label": "", "metadata": {}, "score": "61.29536"}
{"text": "Between July 2003 and June 2008 , 612 patients received a kidney transplant alone at our center .Of these , 464 patients ( 76 % ) were treated with the rapid steroid withdrawal protocol .", "label": "", "metadata": {}, "score": "61.370872"}
{"text": "10.1016/S0033 - 0620(85)80003 - 7 .View Article PubMed .Matas AJ : Chronic progressive calcineurin nephrotoxicity : an overstated concept .Am J Transplant .", "label": "", "metadata": {}, "score": "61.751213"}
{"text": "A total of 24 rats were divided into four groups , which included control , tacrolimus , tacrolimus + olmesartan , and olmesartan groups .Tacrolimus - induced nephrotoxicity was assessed biochemically and histopathologically .", "label": "", "metadata": {}, "score": "62.001038"}
{"text": "It has since been used as induction therapy in many .Page 5 . centers ; over 1,500 transplants in the USA received Campath induction during the 2- year period of 2003 to 2004 [ 7].", "label": "", "metadata": {}, "score": "62.06015"}
{"text": "Recipients were treated with FK778 , tacrolimus , MMF , or sirolimus for 10 days ( acute rejection study ) or 28 days ( chronic OAD study ) at varying doses .", "label": "", "metadata": {}, "score": "62.06075"}
{"text": "PubMed View Article .Dorner T , Radbruch A , Burmester GR : B - cell - directed therapies for autoimmune disease .Nat Rev Rheumatol 2009 , 5 : 433 - 441 .", "label": "", "metadata": {}, "score": "62.150425"}
{"text": "Finally , in vitro smooth muscle cell migration was decreased in the atorvastatin , NE-10790 and manumycin A groups only .FPT and GGPT-2 ( inhibition ) are the key enzymes in the HGM - CoA reductase pathway and most influential in TCAD prevention .", "label": "", "metadata": {}, "score": "62.224777"}
{"text": "There are many potential causes of late graft failure , with the most common being interstitial fibrosis / tubular atrophy ( IF / TA ) [ 3 ] .", "label": "", "metadata": {}, "score": "62.23019"}
{"text": "The Placement of Aortic Transcatheter Valves ( PARTNER ) trial showed that among high - risk patients with aortic stenosis , the 1-year survival rates are similar with transcatheter aortic - valve replacement ( TAVR ) and surgical replacement .", "label": "", "metadata": {}, "score": "62.315746"}
{"text": "Transplantation . 1998;Vol .[ Cross Ref ] [ PubMed ] 16 .Matzinger P. Tolerance , danger , and the extended family .Annu Rev Immunol . 1994;Vol .", "label": "", "metadata": {}, "score": "62.351845"}
{"text": "Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "62.518463"}
{"text": "Abstract .Mesenchymal stem cells ( MSCs ) show differentiation capacity along mesenchymal lineages and have the potential to aid tissue regeneration .MSC transplantation strategies are therefore currently being assessed following injury to various organs .", "label": "", "metadata": {}, "score": "62.53695"}
{"text": "Grafts were harvested after 7 , 30 , and 60 days post - transplant for histologic evaluation and analysis of host cellular and humoral response .", "label": "", "metadata": {}, "score": "62.692528"}
{"text": "10.1097/TP.0b013e318257ad41 .View Article PubMed .Hanaway MJ , Woodle ES , Mulgaonkar S , Peddi VR , Kaufman DB , First MR , Croy R , Holman J : Alemtuzumab induction in renal transplantation .", "label": "", "metadata": {}, "score": "62.69529"}
{"text": "A summary of the treatment scheme and flow of participants through the trial is shown in Figure 1 .Follow - up and documentation During the first year after transplantation , all participants will be followed up at discharge after transplantation and at 1 , 3 , 6 , 9 , and 12 months after transplantation .", "label": "", "metadata": {}, "score": "62.75187"}
{"text": "The 3C Study complies with the principles of Good Clinical Practice .Written informed consent will be obtained from each participant before randomization , after a discussion with the local investigator or their nominated deputy .", "label": "", "metadata": {}, "score": "62.975735"}
{"text": "The 3C Study complies with the principles of Good Clinical Practice .Written informed consent will be obtained from each participant before randomization , after a discussion with the local investigator or their nominated deputy .", "label": "", "metadata": {}, "score": "62.975735"}
{"text": "However , there were only 659 patients in total included in these trials , so substantial uncertainty remains over the efficacy and safety of Campath .", "label": "", "metadata": {}, "score": "63.11853"}
{"text": "However , there were only 659 patients in total included in these trials , so substantial uncertainty remains over the efficacy and safety of Campath .", "label": "", "metadata": {}, "score": "63.11853"}
{"text": "A summary of the treatment scheme and flow of participants through the trial is shown in Figure 1 .Follow - up and documentation .During the first year after transplantation , all participants will be followed up at discharge after transplantation and at 1 , 3 , 6 , 9 , and 12 months after transplantation .", "label": "", "metadata": {}, "score": "63.120117"}
{"text": "Herein we summarize the contemporary outcomes of open surgical repair of patients with either descending thoracic or thoracoabdominal aortic aneurysms , focusing on the risk of complications and means for preventing their occurrence .", "label": "", "metadata": {}, "score": "63.16941"}
{"text": "Participants will be randomized by an internet - based system before transplantation .After the participant is registered on the internet - based system , they are assigned a unique identifier ( participant ID ) , and once randomized , the assigned treatment group is displayed on the screen .", "label": "", "metadata": {}, "score": "63.201878"}
{"text": "The protective anti - apoptotic affects of CryAB may target the endothelial cell . \" Peninsula- Style \" Transverse Aortic Arch Replacement in Patients With Bicuspid Aortic Valve ANNALS OF THORACIC SURGERY Itoh , A. , Fischbein , M. , Arata , K. , Miller , D. C. 2010 ; 90 ( 4 ) : 1369 - 1371 .", "label": "", "metadata": {}, "score": "63.2397"}
{"text": "10.1111/j.1600 - 6143.2006.01495.x .PubMed Central View Article PubMed .Barth RN , Janus CA , Lillesand CA , Radke NA , Pirsch JD , Becker BN , Fernandez LA , Thomas Chin L , Becker YT , Odorico JS : Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation .", "label": "", "metadata": {}, "score": "63.282833"}
{"text": "Abstract .This study investigates the protective effect of exogenous ?B - crystallin ( CryAB ) on myocardial function after ischemia - reperfusion injury .", "label": "", "metadata": {}, "score": "63.447052"}
{"text": "23 , pp .1725 - 1730 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. W. Evans , D. L. Manninen , and L. P. Garrison Jr. , \" The quality of life of patients with end - stage renal disease , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "63.47134"}
{"text": "[PubMed ] 11 .Transplantation .2009;Vol .[ Cross Ref ] [ PubMed ] 12 .Lebranchu Y , Thierry A , Toupance O , Westeel PF , Etienne I , Thervet E , Moulin B , Frouget T , Le Meur Y , Glotz D. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation : concept study .", "label": "", "metadata": {}, "score": "63.500526"}
{"text": "The primary analyses will be performed in all patients who have received a least one dose of the study medication .Sensitivity analyses will be performed in the per protocol population , including all patients that finish the study at the last visit one year after study entry .", "label": "", "metadata": {}, "score": "63.59972"}
{"text": "Trial registration ClinicalTrials.gov , NCT01120028 and ISRCTN88894088 .[ Show abstract ] [ Hide abstract ] ABSTRACT : mTOR inhibitors avoid calcineurin nephrotoxicity , but sirolimus de novo is associated with unacceptable side effects and higher rejection rates .", "label": "", "metadata": {}, "score": "63.81027"}
{"text": "10.1016/S0140 - 6736(10)62318 - 5 .View Article PubMed .Lebranchu Y , Thierry A , Thervet E , Buchler M , Etienne I , Westeel PF , de Ligny HB , Moulin B , Rerolle JP , Frouget T : Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF - four - year results of the Postconcept study .", "label": "", "metadata": {}, "score": "63.853226"}
{"text": "Advice will be given on mouth , care and a short course of low - dose prednisolone can be used to cover the conversion period if the local investigator considers it necessary .", "label": "", "metadata": {}, "score": "64.00026"}
{"text": "Advice will be given on mouth , care and a short course of low - dose prednisolone can be used to cover the conversion period if the local investigator considers it necessary .", "label": "", "metadata": {}, "score": "64.00026"}
{"text": "Aortic root diameters did not correlate with aortic wall thickness .Aortic size , degree of MMD , and elastin loss did not vary significantly between CTD patients .", "label": "", "metadata": {}, "score": "64.05236"}
{"text": "More follow - up is required to determine long - term valve durability and the hazard of other clinically important late adverse events , including eventual reoperation , to beyond 10 years .", "label": "", "metadata": {}, "score": "64.19277"}
{"text": "Patients and Methods .This study was approved by the Mayo Foundation Institutional Review Board ( IRB ) .This is a retrospective study of all adult kidney transplant recipients treated with an RSW protocol who were transplanted at our center between July 2003 and June 2008 .", "label": "", "metadata": {}, "score": "64.230515"}
{"text": "Patients on concurrent immunosuppression with MMF ( CellCept ) or MPS delayed - release tablets ( Myfortic ) who have not been on stable doses for at least 4 weeks before Screening .", "label": "", "metadata": {}, "score": "64.43437"}
{"text": "There are two potential strategies to minimize CNI exposure : more potent induction therapy could be used safely to allow dose reduction or avoidance of CNIs , or CNIs could be replaced by a different class of immunosuppressant that is less likely to damage the kidney .", "label": "", "metadata": {}, "score": "64.992455"}
{"text": "The study is planned to take about 7 years , with recruitment of the 852 participants taking 2 years , followed by a 5-year follow - up period .", "label": "", "metadata": {}, "score": "65.19054"}
{"text": "2954 - 2956 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. J. Dickenmann , V. Nickeleit , D. Tsinalis , L. G\u00fcrke , M. J. Mihatsch , and G. Thiel , \" Why do kidney grafts fail ?", "label": "", "metadata": {}, "score": "65.21377"}
{"text": "Participants allocated tacrolimus - based maintenance therapy will continue their current therapy and the target trough concentration is 5 to 7 ng / ml in all participants .", "label": "", "metadata": {}, "score": "65.26099"}
{"text": "Participants allocated tacrolimus - based maintenance therapy will continue their current therapy and the target trough concentration is 5 to 7 ng / ml in all participants .", "label": "", "metadata": {}, "score": "65.26099"}
{"text": "In vivo BLI revealed near - complete donor cell death 4 weeks after IM transplantation .After intravenous transplantation , BLI revealed that cells migrated to the injured area in the limb , as well as to the liver , spleen , and bone marrow .", "label": "", "metadata": {}, "score": "65.529396"}
{"text": "Kidney transplantation is the best treatment for patients with end - stage renal failure , but uncertainty remains about the best immunosuppression strategy .Long - term graft survival has not improved substantially , and one possible explanation is calcineurin inhibitor ( CNI ) nephrotoxicity .", "label": "", "metadata": {}, "score": "65.66688"}
{"text": "It has since been used as induction therapy in many centers ; over 1,500 transplants in the USA received Campath induction during the 2-year period of 2003 to 2004 [ 7 ] .", "label": "", "metadata": {}, "score": "65.68236"}
{"text": "Basic protocol overview .The 3C Study is an open - label , randomized multi - center trial comparing 1 ) Campath - based and basiliximab - based induction therapy strategies ; and 2 ) from about 6 months after transplantation , sirolimus - based and tacrolimus - based maintenance therapy strategies .", "label": "", "metadata": {}, "score": "65.82887"}
{"text": "Background .Our aim was to study the impact of clinical acute rejection ( CR ) and subclinical rejection ( SR ) on outcomes in kidney transplant recipients treated with rapid steroid withdrawal ( RSW ) .", "label": "", "metadata": {}, "score": "65.84799"}
{"text": "Significant differences were observed in allograft survival between the CR and control group ( HR 9.06 , 95 % CI 3.39 - 24.2 ) and between the SR and control group ( HR 4.22 , 95 % CI 1.30 - 13.7 ) .", "label": "", "metadata": {}, "score": "65.90605"}
{"text": "Seven of the 18 patients with Banff borderline changes in the SR group remained on corticosteroids , and 2 of the 4 patients with borderline changes in the CR group remained on corticosteroids after the initial treatment .", "label": "", "metadata": {}, "score": "65.97908"}
{"text": "In our population this could be explained by the use of less effective immunosuppression , reporting to the state of the art before the year 2000 .", "label": "", "metadata": {}, "score": "66.06751"}
{"text": "Abstract .A 180/180 \u00b0 configuration has been reported to increase repair durability after valve - sparing aortic root replacement ( V - SARR ) for bicuspid aortic valve ( BAV ) disease .", "label": "", "metadata": {}, "score": "66.13028"}
{"text": "Steinmetz OM , Lange - Husken F , Turner JE , Vernauer A , Helmchen U , Stahl RA , Thaiss F , Panzer U : Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection .", "label": "", "metadata": {}, "score": "66.17872"}
{"text": "All patients were routinely tested for BK viremia at months 1 , 4 and annually .A diagnosis of BK nephropathy required BK viremia and a biopsy demonstrating BK by in situ hybridization .", "label": "", "metadata": {}, "score": "66.2115"}
{"text": "Journal .Page 3 .Categories Subject : Clinical Trial Protocol Keywords Kidney transplantation Alemtuzumab Campath Sirolimus Randomized controlled trial Basiliximab Tacrolimus Abstract Background Kidney transplantation is the best treatment for patients with end - stage renal failure , but uncertainty remains about the best immunosuppression strategy .", "label": "", "metadata": {}, "score": "66.216545"}
{"text": "Transthoracic echocardiogram was performed at 6 \u00b1 3 days and at 2.9 \u00b1 2.1 years .Functional end - points included freedom from aortic regurgitation ( AR ) 1 + , AR 2 + and freedom from AR progression ( 0 to 1 + , or 1 + to 2 + ) .", "label": "", "metadata": {}, "score": "66.2326"}
{"text": "But when we combined the two rejection groups ( SR and CR ) we found that patients with Banff borderline changes had a worse outcome compared to the control group without rejection .", "label": "", "metadata": {}, "score": "66.32275"}
{"text": "Histopathological and ultrastructural studies showed that aliskiren attenuated tacrolimus - induced renal damage .These results suggest that aliskiren has protective effects against tacrolimus - induced nephrotoxicity ; implying that renin inhibitor may counteract nephrotic syndrome associated with immunosuppressant use .", "label": "", "metadata": {}, "score": "66.32533"}
{"text": "Continuous variables will be compared with t - tests ( after logarithmic transformation if necessary for skewed variables ) .Tertiary endpoints ( that is , subgroup analyses of the primary endpoint in different types of participants ) will be interpreted cautiously , as the power to detect true differences between subgroups will be limited .", "label": "", "metadata": {}, "score": "66.3533"}
{"text": "Either CryAB ( 50 ? g ) or phosphate - buffered saline ( 100 ?Intraperitoneal injections were administered every other day .Left ventricular ejection fraction was evaluated on postoperative day 40 with magnetic resonance imaging .", "label": "", "metadata": {}, "score": "66.87559"}
{"text": "605 - 612 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Alarrayed , A. El - Agroudy , A. Al - Arrayed , et al . , \" Why does kidney allograft fail ?", "label": "", "metadata": {}, "score": "66.883194"}
{"text": "in 2 divided doses ) .A small number received alemtuzumab ( 30 mg given SQ in a single dose ) as part of a separate IRB - approved protocol .", "label": "", "metadata": {}, "score": "66.8848"}
{"text": "This same study concluded that much of the chronic damage is due to CNI toxicity , even though the levels of these drugs in the study had been maintained within the target range .", "label": "", "metadata": {}, "score": "66.90045"}
{"text": "The RIACT study is a double - blind , randomized , placebo - controlled phase III trial .Randomization will be performed centrally stratified by study center .", "label": "", "metadata": {}, "score": "67.16106"}
{"text": "The primary endpoint of the maintenance therapy comparison will be change in graft function ( estimated using the four - variable Modification of Diet in Renal Disease ( MDRD ) formula [ 25 ] ) from 6 months to 2 years after transplantation .", "label": "", "metadata": {}, "score": "67.29178"}
{"text": "The primary endpoint of the maintenance therapy comparison will be change in graft function ( estimated using the four - variable Modification of Diet in Renal Disease ( MDRD ) formula [ 25 ] ) from 6 months to 2 years after transplantation .", "label": "", "metadata": {}, "score": "67.29178"}
{"text": "Detailed Description .Recipients of kidney transplant 3 months to 5 years before Screening and on a stable dose of Prograf will be randomly assigned to be converted from Prograf twice daily to LCP - Tacro once daily or to remain on maintenance therapy with Prograf twice daily .", "label": "", "metadata": {}, "score": "67.34476"}
{"text": "2009;Vol .[ Cross Ref ] [ PubMed ] 13 .Lancet .2011;Vol .[ Cross Ref ] [ PubMed ] 14 .Lebranchu Y , Thierry A , Thervet E , Buchler M , Etienne I , Westeel PF , de Ligny HB , Moulin B , Rerolle JP , Frouget T. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF - four - year results of the Postconcept study .", "label": "", "metadata": {}, "score": "67.443665"}
{"text": "The results of Study 3 are shown in Table 2 .These results are consistent with the findings from Study 1 and Study 2 .Table 2 .", "label": "", "metadata": {}, "score": "67.5898"}
{"text": "2004;Vol .[ Cross Ref ] [ PubMed ] 3 .Chapman JR , O'Connell PJ , Nankivell BJ .Chronic renal allograft dysfunction .J Am Soc Nephrology : JASN .", "label": "", "metadata": {}, "score": "67.6398"}
{"text": "Sites will be monitored during recruitment and follow - up through a combination of on - site visits from the sponsor and central statistical monitoring .", "label": "", "metadata": {}, "score": "67.71803"}
{"text": "Study drugs will be purchased by participating hospitals , and the Campath will be relabeled by local hospital pharmacies in accordance with the EU Clinical Trial Directive .", "label": "", "metadata": {}, "score": "67.768036"}
{"text": "Animals were divided into four groups .Tacrolimus - induced nephrotoxicity was assessed biochemically and histopathologically .Treatment with aliskiren decreased the tacrolimus - induced changes in biochemical markers of nephrotoxicity such as blood urea nitrogen and creatinine .", "label": "", "metadata": {}, "score": "67.77811"}
{"text": "Two potential strategies to reduce exposure to CNIs are Campath as a more potent induction therapy , and conversion to a sirolimus - based maintenance regimen .", "label": "", "metadata": {}, "score": "67.941315"}
{"text": "Two potential strategies to reduce exposure to CNIs are Campath as a more potent induction therapy , and conversion to a sirolimus - based maintenance regimen .", "label": "", "metadata": {}, "score": "67.941315"}
{"text": "If these differences were maintained , it would be reasonable to anticipate a 10 ml / min/1.73 m 2 difference in eGFR 2 years after conversion to sirolimus ( that is , median follow - up at least 2.5 years after transplantation ) .", "label": "", "metadata": {}, "score": "67.95109"}
{"text": "Application of rituximab for any reason 12 months prior inclusion .Active CMV , HIV , replicative Hepatitis B or C , or other relevant infections .", "label": "", "metadata": {}, "score": "67.97654"}
{"text": "Study Type ICMJE .Interventional .Study Phase .Phase 3 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "68.09621"}
{"text": "Trials of late conversion to sirolimus failed to show any benefit [ 11 ] , but more recently trials of early ( that is , within 3 to 6 months post- transplant ) conversion to sirolimus have shown potential .", "label": "", "metadata": {}, "score": "68.107346"}
{"text": "To achieve the highest degree of comparability and to reduce inter - center variability in the histopathological diagnosis , all pathologists will be provided with the same automated immunohistochemical staining platform ( BondMaxTM , A. Menarini Diagnostics , Berlin , Germany ) .", "label": "", "metadata": {}, "score": "68.22695"}
{"text": "2011;Vol .[ Cross Ref ] 10 .Flechner SM .Reviewing the evidence for de novo immunosuppression with sirolimus .Transplant Proc . 2008;Vol .", "label": "", "metadata": {}, "score": "68.33112"}
{"text": "Tacrolimus aerosol reduces systemic side effects and effectively protects the airway graft from early cellular rejection and chronic obliterative airway disease .Techniques for experimental heterotopic and orthotopic tracheal transplantations - When to use which model ?", "label": "", "metadata": {}, "score": "68.60573"}
{"text": "Inclusion criteria .The specific inclusion criteria are recipients of a kidney - only transplant aged over 18 years .Exclusion criteria .Study objectives .", "label": "", "metadata": {}, "score": "69.12378"}
{"text": "Both .Ages .18 Years and older .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Abstract .", "label": "", "metadata": {}, "score": "69.726974"}
{"text": "Competing interest .The authors declare no conflicts of interest .Authors ' contributions .LS , WG , MS , SM , AS , MM and HH conceived the study .", "label": "", "metadata": {}, "score": "69.739044"}
{"text": "Freedom from reoperation ( all causes ) on the aortic root was 92.2 % \u00b1 3.6 % at 10 years ; 3 reoperations were aortic valve replacement owing to structural valve deterioration .", "label": "", "metadata": {}, "score": "69.9044"}
{"text": "In a recent analysis , more than 30 % of kidney recipients in the USA are treated with RSW protocols [ 12 ] .Several studies have demonstrated that short- and intermediate - term outcomes are similar to steroid - treated patients [ 12 ] .", "label": "", "metadata": {}, "score": "70.01784"}
{"text": "PubMed View Article .Fleming TR , Harrington DP , O'Brien PC : Designs for group sequential tests .Control Clin Trials 1984 , 5 : 348 - 361 .", "label": "", "metadata": {}, "score": "70.30307"}
{"text": "The protocol is intended to be pragmatic and easy to implement at local transplant centers .Considerable effort has been made to make the control treatment as similar to current European practice as possible to ensure that centers would be willing to deliver it to participants and to ensure that the results will be relevant to current practice .", "label": "", "metadata": {}, "score": "70.31368"}
{"text": "The protocol is intended to be pragmatic and easy to implement at local transplant centers .Considerable effort has been made to make the control treatment as similar to current European practice as possible to ensure that centers would be willing to deliver it to participants and to ensure that the results will be relevant to current practice .", "label": "", "metadata": {}, "score": "70.31368"}
{"text": "PubMed .Nickerson P , Jeffery J , Gough J , McKenna R , Grimm P , Cheang M , Rush D : Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant .", "label": "", "metadata": {}, "score": "70.544464"}
{"text": "Patients unable to swallow study medication .Patients incapable of understanding the purposes and risks of the study , who can not give written informed consent and who are unwilling or unable to comply with the study protocol requirements .", "label": "", "metadata": {}, "score": "70.63324"}
{"text": "Molecular and genetic mechanisms of aortic aneurysm / dissection development .Molecular mechanisms of aneurysm formation in Marfan Syndrome .Clinical research interests include thoracic aortic diseases ( aneurysms , dissections ) .", "label": "", "metadata": {}, "score": "70.63985"}
{"text": "Ann Intern Med .View Article PubMed .Mulay AV , Cockfield S , Stryker R , Fergusson D , Knoll GA : Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction : a systematic review of the evidence .", "label": "", "metadata": {}, "score": "70.65904"}
{"text": "Apoptosis was then assessed by western blot ( Bcl-2 , free bax , cleaved caspases-3 , 9 , PARP ) and enzyme - linked immunosorbent assay analyses ( cytoplasmic histone - associated DNA fragments and caspase-3 activity ) .", "label": "", "metadata": {}, "score": "70.73619"}
{"text": "Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days before receiving study drug .Exclusion Criteria : .Recipients of any transplanted organ other than kidney .", "label": "", "metadata": {}, "score": "71.012314"}
{"text": "Inclusion Criteria : .Men and women at least 18 years of age who are recipients of a kidney transplant between 3 months and 5 years before the screening date .", "label": "", "metadata": {}, "score": "71.060715"}
{"text": "Acknowledgements .The study is supported by a grant from the German government ( BMBF , Clinical Studies Programme ) .Study and protocol design were supported by the integrated research and treatment transplantation center ( IFB - Tx ) .", "label": "", "metadata": {}, "score": "71.213715"}
{"text": "Rituximab is a B - cell depleting antibody which is directed against the CD20 epitope and leads to apoptosis of mature B cells .It has been approved for treatment of diseases with B - cell activity , such as B cell lymphoma and rheumatoid arthritis [ 12 ] .", "label": "", "metadata": {}, "score": "71.256096"}
{"text": "10.1111/j.1600 -6143.2004.00515.x .View Article PubMed .Chapman JR , O'Connell PJ , Nankivell BJ : Chronic renal allograft dysfunction .J Am Soc Nephrology : JASN .", "label": "", "metadata": {}, "score": "71.28922"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Tacrolimus is frequently used as immunosuppressive agent in organ transplantation but its clinical use is limited due to its marked nephrotoxicity .", "label": "", "metadata": {}, "score": "71.43291"}
{"text": "Reasons for exclusion also include malignant tumors , cardiac diseases , such as heart insufficiency ( New York Heart Association ( NYHA ) III - IV ) or severe arrhythmia ( Table 1 ) .", "label": "", "metadata": {}, "score": "71.45999"}
{"text": "The study is recruiting patients .Collaborators .F. Eitner , G. Kroll , A. M\u00fchlfeld ( Department of Nephrology , RWTH University Hospital , Aachen , Germany ) .", "label": "", "metadata": {}, "score": "72.09699"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. W. Bingaman , C. L. Murphey , J. Palma - Vargas , and F. Wright , \" A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "72.13051"}
{"text": "After IV injection of MSC suspensions ( with or without SN ) , their dynamic distribution was monitored by in vivo luciferine imaging as well as by histopathology .", "label": "", "metadata": {}, "score": "72.25496"}
{"text": "Following these findings and with the aim to keep the dosage of rituximab and , therefore , possible side effects as low as possible , rituximab will be given generally only once in the RIACT study .", "label": "", "metadata": {}, "score": "72.43199"}
{"text": "2011;Vol .[ Cross Ref ] [ PubMed ] 15 .Li Y , Zheng XX , Li XC , Zand MS , Strom TB .", "label": "", "metadata": {}, "score": "72.67781"}
{"text": "Furthermore , a urine status will be assessed ( leukocytes , nitrite , protein , haemoglobin ) .To exclude pregnancy at the time of inclusion , \u00df - HCG - levels in female patients are measured .", "label": "", "metadata": {}, "score": "72.926025"}
{"text": "Trial registration .Keywords .Kidney transplantation Alemtuzumab Campath Sirolimus Randomized controlled trial Basiliximab Tacrolimus .Electronic supplementary material .The online version of this article ( doi : 10 .", "label": "", "metadata": {}, "score": "73.04549"}
{"text": "We describe a simple \" peninsula - style \" technique of transverse arch replacement used in conjunction with valve - sparing aortic root replacement for patients with a bicuspid aortic valve .", "label": "", "metadata": {}, "score": "73.14035"}
{"text": "TCAD was assessed by morphometric analysis at Day 52 .Graft - infiltrating cells , cytokine production , smooth muscle cell proliferation and migration and endothelial cell MHC II expression were detected on Day 7 .", "label": "", "metadata": {}, "score": "73.151146"}
{"text": "Participating centers .Major kidney transplant centers from the UK ( 18 sites in total ) will be participating in the study .Such a collaboration is required in order to recruit the planned number of kidney - transplant patients needed to provide statistically reliable and clinically meaningful results .", "label": "", "metadata": {}, "score": "73.37126"}
{"text": "Perillyl alcohol treatment resulted in a trend toward decreased luminal narrowing .Finally , zaragozic acid ( cholesterol blockade only ) did not alter TCAD severity .", "label": "", "metadata": {}, "score": "73.425095"}
{"text": "Authors ' contributions RH contributed to the study design , coordination , approval processes , and acquisition of data , and drafted the manuscript .PF initiated the study concept and design , and reviewed the paper .", "label": "", "metadata": {}, "score": "73.55124"}
{"text": "Participating centers Major kidney transplant centers from the UK ( 18 sites in total ) will be participating in the study .Such a collaboration is required in order to recruit the planned number of kidney - transplant patients needed to provide statistically reliable and clinically meaningful results .", "label": "", "metadata": {}, "score": "73.77077"}
{"text": "The study will be carried out in Germany by , so far , 13 leading kidney transplant centers .The study design is illustrated in Figure 1 .", "label": "", "metadata": {}, "score": "73.78369"}
{"text": "Monitoring Before recruitment started , all sites were visited by the sponsor in order to train the relevant staff in the study procedures .Recruitment rates and completeness of follow- up data will be monitored closely by the sponsor .", "label": "", "metadata": {}, "score": "73.817184"}
{"text": "( TGF- ? ) signaling .Although TGF- ? blockade prevents aneurysms in MFS mouse models , the mechanisms through which excessive TGF- ? causes aneurysms remain ill - defined .", "label": "", "metadata": {}, "score": "73.9012"}
{"text": "Other studies have suggested that HLA matching is of diminishing significance , while nonimmunologic factors remain equivalently important [ 24 ] .In 2003 , the US kidney allocation system was changed to eliminate priority for HLA - B similarity .", "label": "", "metadata": {}, "score": "73.94467"}
{"text": "Figure 1 Flowchart showing study treatments and randomizations , including proposed analyses .The specific inclusion criteria are recipients of a kidney - only transplant aged over 18 years .", "label": "", "metadata": {}, "score": "73.9861"}
{"text": "Tertiary endpoints ( that is , subgroup analyses of the primary endpoint in different types of participants ) will be interpreted cautiously , as the power to detect true differences between subgroups will be limited .", "label": "", "metadata": {}, "score": "74.471565"}
{"text": "Renal Failure .Intervention ICMJE .Drug : LCP - Tacro .LCP - Tacro tablets will be administered orally QD , at the same time in the morning to maintain trough levels at 5 - 15 ng / ML .", "label": "", "metadata": {}, "score": "74.53339"}
{"text": "Within seconds after MSC IV injection , the vast majority of cells was found in the lungs .However , cell trapping in the pulmonary microvasculature was significantly reduced by pre - treatment with SN.We demonstrate that cell trapping in lungs can be reduced with IV SN pretreatment , increasing MSC passage through the lung capillaries , and potentially facilitating cell access to injured organs .", "label": "", "metadata": {}, "score": "74.58185"}
{"text": "Churchill Hospital , Headington .The 3C Study Collaborative Group .References .Wolfe RA , Ashby VB , Milford EL , Ojo AO , Ettenger RE , Agodoa LYC , Held PJ , Port FK : Comparison of mortality in all patients on dialysis , patients on dialysis awaiting transplantation , and recipients of a first cadaveric transplant 10.1056/NEJM199912023412303 .", "label": "", "metadata": {}, "score": "74.684166"}
{"text": "LS , WG and MS wrote the first draft of this paper , which has been critically revised by all co - authors .All authors have read and approved the final version of the manuscript .", "label": "", "metadata": {}, "score": "74.745766"}
{"text": "Authors ' contributions .RH contributed to the study design , coordination , approval processes , and acquisition of data , and drafted the manuscript .", "label": "", "metadata": {}, "score": "74.89916"}
{"text": "Patients with GT requiring cardiac surgical procedures are at high risk for perioperative bleeding complications .This case report illustrates the importance of multidisciplinary planning , TEG analysis , and the judicious use of recombinant factors to minimize operative bleeding risk .", "label": "", "metadata": {}, "score": "75.83059"}
{"text": "Ethics statement .The study was approved by the ethics committee of Hannover Medical School as the leading center and the Paul Ehrlich Institute , as well as by all local ethics committees of the participating centers .", "label": "", "metadata": {}, "score": "76.01659"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Tacrolimus , a calcineurin inhibitor , is clinically used as an immunosuppressive agent in organ transplantation , but its use is limited due to its marked nephrotoxicity .", "label": "", "metadata": {}, "score": "76.06971"}
{"text": "All statistical analysis was performed using SPSS software for Windows ( version 18.0 ; Chicago , USA ) .Results are presented as median and interquartiles range for continuous variables and as frequency and percentages ( . were considered statistically significant .", "label": "", "metadata": {}, "score": "76.2067"}
{"text": "Prophylactic PLT administration was continued through the immediate postoperative period and no bleeding complications occurred .Thromboelastograms ( TEGs ) were used in conjunction with traditional hematologic laboratory analysis to optimize clinical management .", "label": "", "metadata": {}, "score": "76.22429"}
{"text": "V. Kliem , P. Weithofer , ( Department of Internal Medicine and Nephrology , Nephrologisches Zentrum Niedersachsen , Hann .Muenden , Germany ) .M. Schad , B. Suwelack , ( University Hospital Muenster , Muenster , Germany ) .", "label": "", "metadata": {}, "score": "76.236336"}
{"text": "Department of Pathology , Hannover Medical School .References .KDIGO clinical practice guideline for the care of kidney transplant recipients Am J Transplant 2009 , 9 ( Suppl 3 ) : S1-S155 .", "label": "", "metadata": {}, "score": "76.266556"}
{"text": "HLA Antibody Analysis .The analysis of anti HLA class I antibodies was carried out by Single Antigen ( Tepnel Lifecodes LSA Stamford CT , Diagnostica Longwood ) according to manufacturer 's instruction .", "label": "", "metadata": {}, "score": "76.457535"}
{"text": "Stanford Advisees .Graduate and Fellowship Programs .All Publications .Abstract .-Ascending aortic dissection and rupture remain a life - threatening complication in patients with Marfan syndrome ( MFS ) .", "label": "", "metadata": {}, "score": "76.479836"}
{"text": "Mouse MSCs were isolated , purified , transfected with firefly luciferase , and labeled with CSFE .Their size was assessed in vitro .To estimate the diameter of mouse pulmonary capillaries , fluorescence - labeled microspheres of different sizes were injected with or without sodium nitroprusside ( SN ) pretreatment .", "label": "", "metadata": {}, "score": "76.5341"}
{"text": "Mechanistically , during apoptosis , caspases are expressed on the cell surface of SMCs and likely contribute to elastin degradation and aneurysm development in Marfan syndrome .", "label": "", "metadata": {}, "score": "76.5479"}
{"text": "View Article PubMed .Matzinger P : Tolerance , danger , and the extended family .Annu Rev Immunol .10.1146/annurev.iy.12.040194.005015 .View Article PubMed .", "label": "", "metadata": {}, "score": "76.80711"}
{"text": "PG has received honoraria from Roche and Novartis .KR has received honoraria from Astellas .AA , MA , SB , PC , AH , IM , GJ , NK , JN , CNa , CNe , CP , RP , AS , NS , PR , and CW have no conflicts of interest to declare .", "label": "", "metadata": {}, "score": "76.87053"}
{"text": "PG has received honoraria from Roche and Novartis .KR has received honoraria from Astellas .AA , MA , SB , PC , AH , IM , GJ , NK , JN , CNa , CNe , CP , RP , AS , NS , PR , and CW have no conflicts of interest to declare .", "label": "", "metadata": {}, "score": "76.87053"}
{"text": "If these differences were maintained , it would be reasonable to anticipate a 10 ml /min/1.73m2 difference in eGFR 2 years after conversion to sirolimus ( that is , median follow - up at .", "label": "", "metadata": {}, "score": "77.21914"}
{"text": "W. Arns , A. Huppertz ( Clinic Cologne - Merheim , Cologne , Germany ) . A. Habicht , M. Fischereder ( Nephrologisches Zentrum , Medizinische Poliklinik Innenstadt , Klinikum der Ludwig - Maximilians - Universit\u00e4t M\u00fcnchen , M\u00fcnchen , Germany ) .", "label": "", "metadata": {}, "score": "77.34877"}
{"text": "PubMed View Article .Froissart M , Rossert J , Jacquot C , Paillard M , Houillier P : Predictive performance of the modification of diet in renal disease and Cockcroft - Gault equations for estimating renal function .", "label": "", "metadata": {}, "score": "77.46414"}
{"text": "Page 19 . role of immunosuppressive drugs .J Am Soc Nephrology : JASN .2007;Vol .[ Cross Ref ] 1 Servi\u00e7o de Nefrologia , Hospital de Santo Ant\u00f3nio , 4099 - 001 Porto , Portugal 2 Servi\u00e7o de Nefrologia , Hospital de Faro , Rua Le\u00e3o Penedo , 8000 Faro , Portugal .", "label": "", "metadata": {}, "score": "77.55501"}
{"text": "The other investigation medicinal products ( basiliximab , tacrolimus , and sirolimus ) will be exempt from the EU Clinical Trial Directive requirements for labeling and accountability , as they will be used within the terms of the marketing authorization .", "label": "", "metadata": {}, "score": "77.74414"}
{"text": "242 - 249 , 2004 .View at Google Scholar \u00b7 View at Scopus . D. N. Rush , J. R. Jeffery , and J. Gough , \" Sequential protocol biopsies in renal transplant patients : clinico - pathological correlations using the banff schema , \" Transplantation , vol .", "label": "", "metadata": {}, "score": "77.85685"}
{"text": "PubMed Central View Article PubMed .Chapman JR : Chronic calcineurin inhibitor nephrotoxicity - lest we forget .Am J Transplant .10.1111/j.1600 - 6143.2011.03504.x .", "label": "", "metadata": {}, "score": "78.60616"}
{"text": "Treatment with olmesartan reversed tacrolimus - induced changes in the biochemical markers ( BUN and creatinine ) of nephrotoxicity .Tacrolimus significantly decreased GSH level and catalase activity while increasing MDA level .", "label": "", "metadata": {}, "score": "79.016556"}
{"text": "2006;Vol .[ Cross Ref ] [ PubMed ] 19 .Barth RN , Janus CA , Lillesand CA , Radke NA , Pirsch JD , Becker BN , Fernandez LA , Thomas Chin L , Becker YT , Odorico JS .", "label": "", "metadata": {}, "score": "79.16701"}
{"text": "Participants assigned basiliximab - based induction will receive 20 mg basiliximab intravenously pre - operatively and on day 4 , oral mycophenolate sodium ( 540 to 720 mg twice daily ) and oral tacrolimus ( 0.05 to 0.10 mg / kg twice daily , aiming for target trough concentration 5 to 12 ng / ml ) .", "label": "", "metadata": {}, "score": "79.25011"}
{"text": "Participants assigned basiliximab - based induction will receive 20 mg basiliximab intravenously pre - operatively and on day 4 , oral mycophenolate sodium ( 540 to 720 mg twice daily ) and oral tacrolimus ( 0.05 to 0.10 mg / kg twice daily , aiming for target trough concentration 5 to 12 ng / ml ) .", "label": "", "metadata": {}, "score": "79.25011"}
{"text": "To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease Not Recruiting .Study Type : Interventional Study Design : Treatment , Open Label , Uncontrolled , Single Group Assignment , Safety and Efficacy study Official Title : A Clinical Study of the TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Diseases for Non - Surgical Candidates under the Physician Sponsored IDE .", "label": "", "metadata": {}, "score": "79.39322"}
{"text": "Interstitial fibrosis / tubular atrophy .MDRD : .Modification of Diet in Renal Disease .NHS : .National Health Service .Declarations .Acknowledgements .", "label": "", "metadata": {}, "score": "79.575"}
{"text": "Safety and Efficacy of LCP - Tacro \u2122 Once Daily in Stable Renal Transplant Patients Converted From Prograf \u00ae Twice Daily .Official Title ICMJE .", "label": "", "metadata": {}, "score": "79.75348"}
{"text": "553 - 559 , 1985 .View at Google Scholar \u00b7 View at Scopus . A. J. Matas , K. J. Gillingham , A. Humar et al . , \" 2202", "label": "", "metadata": {}, "score": "79.98953"}
{"text": "Unless there is a problem , you would not need to have your chest opened .Stanford is currently not accepting patients for this trial .", "label": "", "metadata": {}, "score": "80.160446"}
{"text": "Maintenance oral immunosuppression will consist of mycophenolate sodium ( 360 mg twice daily ) and tacrolimus ( starting at 2 mg twice daily from day 3 , aiming for target trough concentration 5 to 7 ng / ml ) .", "label": "", "metadata": {}, "score": "80.34286"}
{"text": "Maintenance oral immunosuppression will consist of mycophenolate sodium ( 360 mg twice daily ) and tacrolimus ( starting at 2 mg twice daily from day 3 , aiming for target trough concentration 5 to 7 ng / ml ) .", "label": "", "metadata": {}, "score": "80.34286"}
{"text": "5 , pp .563 - 568 , 1997 .View at Google Scholar \u00b7 View at Scopus The safety and efficacy of Simulect \u00ae ( basiliximab ) for the prophylaxis of acute organ rejection in adults following cadaveric- or living - donor renal transplantation were assessed in four randomized , double - blind , placebo - controlled clinical studies ( 1,184 patients ) .", "label": "", "metadata": {}, "score": "80.38105"}
{"text": "You are invited to participate in a research study for treatment of aneurysms of the descending thoracic aorta .The investigational device , called the TAG Thoracic Endoprosthesis ( device ) has been designed to simplify treatment of aneurysms of the descending thoracic aorta .", "label": "", "metadata": {}, "score": "80.52232"}
{"text": "Tacrolimus was started when the serum creatinine dropped by at least 30 % , or by post - op day 4 .The goal for trough tacrolimus levels was 10 - 12 ng / mL for the first 30 days , 8 - 10 ng / mL between days 30 - 90 , and 5 - 8 ng / mL after 90 days .", "label": "", "metadata": {}, "score": "80.58737"}
{"text": "Campath is a potent induction agent .Campath ( alemtuzumab ) is a humanized monoclonal antibody directed against CD52 , and causes depletion of lymphocytes .", "label": "", "metadata": {}, "score": "80.757355"}
{"text": "It blocks the mammalian target of rapamycin pathway , thus inhibiting cellular proliferation .Sirolimus has been used in a variety of strategies for kidney transplantation .", "label": "", "metadata": {}, "score": "80.90048"}
{"text": "CS and AAZ are in charge of pharmacovigilance and prepared the data monitoring committee charter .KP manages the FACS analysis of the study .MD , VB , JB and JT will evaluate the allograft biopsies ; MD developed a histological scoring system for the B - cell infiltrates .", "label": "", "metadata": {}, "score": "81.13405"}
{"text": "Normally distributed variables are expressed as mean \u00b1 standard deviation ( SD ) and nonnormally distributed variables are expressed as median and interquartile range ( IQR ) .", "label": "", "metadata": {}, "score": "81.205185"}
{"text": "In tacrolimus group histological examination showed marked changes in renal tubule , mitochondria , and podocyte processes .Histopathological and ultrastructural studies showed that treatment with olmesartan prevented tacrolimus - induced renal damage .", "label": "", "metadata": {}, "score": "81.2153"}
{"text": "2007;Vol .[ Cross Ref ] 6 .Friend PJ , Rebello P , Oliveira D , Manna V , Cobbold SP , Hale G , Jamieson NV , Jamieson I , Calne RY , Harris DT .", "label": "", "metadata": {}, "score": "81.31505"}
{"text": "Trial organization .Page 10 .The 3C Study is an investigator - initiated trial .Preliminary investigator meetings were organized by the University of Oxford , which is the sponsor of the study .", "label": "", "metadata": {}, "score": "81.34583"}
{"text": "Page 16 .Wolfe RA , Ashby VB , Milford EL , Ojo AO , Ettenger RE , Agodoa LYC , Held PJ , Port FK .", "label": "", "metadata": {}, "score": "81.508865"}
{"text": "Although the optimal surgical treatment of the dilated aortic arch is controversial in patients with a bicuspid aortic valve , such exists in more than 70 % of bicuspid aortic valve patients .", "label": "", "metadata": {}, "score": "81.59232"}
{"text": "Treg cells dampen the effector response to antigenic challenge and are a crucial element of peripheral tolerance .Furthermore , in addition to its effects on tolerance - promoting Treg cells , sirolimus facilitates the deletion of effector alloreactive T cells [ 22].", "label": "", "metadata": {}, "score": "81.60378"}
{"text": "Treg cells dampen the effector response to antigenic challenge and are a crucial element of peripheral tolerance .Furthermore , in addition to its effects on tolerance - promoting Treg cells , sirolimus facilitates the deletion of effector alloreactive T cells [ 22 ] .", "label": "", "metadata": {}, "score": "81.60378"}
{"text": "This is obviously encouraging , and merits further investigation .Based on these observations , we have designed a clinical trial with the purpose of testing whether Campath and/or sirolimus can improve long - term outcomes after kidney transplantation .", "label": "", "metadata": {}, "score": "81.71874"}
{"text": "This is obviously encouraging , and merits further investigation .Based on these observations , we have designed a clinical trial with the purpose of testing whether Campath and/or sirolimus can improve long - term outcomes after kidney transplantation .", "label": "", "metadata": {}, "score": "81.71874"}
{"text": "Clinical Data .We conducted a retrospective study and analyzed data from a total of 996 kidney transplants ( KT ) performed between July of 1983 and June of 2000 , at Hospital de Santo Ant\u00f3nio , Porto , Portugal .", "label": "", "metadata": {}, "score": "82.62157"}
{"text": "Abstract .Interleukin-17 ( IL-17 ) , which is predominantly produced by T helper 17 cells distinct from T helper 1 or T helper 2 cells , participates in the pathogenesis of infectious , autoimmune , and allergic disorders .", "label": "", "metadata": {}, "score": "83.065765"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "83.0968"}
{"text": "Royal London Hospital , Barts Health NHS Trust : C Puliatti , C Rolfe , V Deelchand , J Smith .Northern General Hospital , Sheffield Teaching Hospitals NHS Foundation Trust : C Nathan , W McKane , L Edwards , F Okhuoya , C King .", "label": "", "metadata": {}, "score": "83.30256"}
{"text": "Trial organization .The 3C Study is an investigator - initiated trial .Preliminary investigator meetings were organized by the University of Oxford , which is the sponsor of the study .", "label": "", "metadata": {}, "score": "83.62793"}
{"text": "Coordinating center ( Clinical Trial Service Unit , University of Oxford ) .Computing coordinators : A Baxter , K Jayne , M Lay .Statistics and computing : R Al - Saidi , I Barton , Y Bu , P Cleverley , M Craig , A Delmestri , P Harding , S Tochlin .", "label": "", "metadata": {}, "score": "84.116806"}
{"text": "Page 6 .The combination of Campath and sirolimus may enable exposure to CNIs to be reduced or eliminated .This could be favorable because CNIs are nephrotoxic and may interfere with tolerogenesis [ 15].", "label": "", "metadata": {}, "score": "84.68205"}
{"text": "Rupture and dissection of aortic root aneurysms remain the leading causes of death in patients with the Marfan syndrome , a hereditary connective tissue disorder that affects 1 in 5000 individuals worldwide .", "label": "", "metadata": {}, "score": "84.70868"}
{"text": "M. Wiesener , K. Hilgers , K.-U. Eckardt ( Department of Nephrology and Hypertension , Friedrich - Alexander - University , ) .O. Witzke , ( Department of Nephrology , University Hospital Essen , University Duisburg - Essen , Essen , Germany ) .", "label": "", "metadata": {}, "score": "87.24901"}
{"text": "Chapman JR .Chronic calcineurin inhibitor nephrotoxicity - lest we forget .Am J Transplant .2011;Vol .[ Cross Ref ] [ PubMed ] 30 .", "label": "", "metadata": {}, "score": "87.53456"}
{"text": "The device reinforces the weakened part of the aorta from the inside .Blood flows through the device to the arteries that go to your abdomen and legs .", "label": "", "metadata": {}, "score": "87.54692"}
{"text": "Study Arm ( s ) .Experimental : LCP - Tacro .LCP - Tacro tablets \u2122 , once daily ( LifeCycle Pharma A / S , Hoersholm DK ) .", "label": "", "metadata": {}, "score": "87.87466"}
{"text": "Abstract .BACKGROUND : Glanzmann thrombasthenia ( GT ) is an autosomal recessive disorder in which the platelet ( PLT ) glycoprotein IIb / IIIa complex is either deficient or dysfunctional .", "label": "", "metadata": {}, "score": "88.0622"}
{"text": "Drug : Prograf .Oral prograf doses will be given BID ( in the morning and evening ) , to maintain trough levels of 5- 15 ng / mL. Prograf capsules ( tacrolimus ) capsules , twice daily oral , provided in 0.5 mg , 1 mg , and 5 mg capsules .", "label": "", "metadata": {}, "score": "88.52517"}
{"text": "An independent data monitoring committee ( DMC ) has been convened ( see below ) .Ethics and safety The most recently approved version of the protocol is version 5 , which was approved by the Nottingham 2 Research Ethics Committee on 28 February 2012 .", "label": "", "metadata": {}, "score": "89.15623"}
{"text": "Marfan syndrome ( MFS ) is a systemic connective tissue disorder notable for the development of aortic root aneurysms and the subsequent life - threatening complications of aortic dissection and rupture .", "label": "", "metadata": {}, "score": "89.26928"}
{"text": "Brief Summary .Patients on a stable dose of Prograf \u00ae will be randomly assigned to be converted from Prograf \u00ae twice daily to LCP Tacro \u2122 once daily or to remain on maintenance therapy with Prograf \u00ae twice daily .", "label": "", "metadata": {}, "score": "89.675735"}
{"text": "Ethics and safety .The most recently approved version of the protocol is version 5 , which was approved by the Nottingham 2 Research Ethics Committee on 28 February 2012 .", "label": "", "metadata": {}, "score": "89.98726"}
{"text": "Recruitment Information .Recruitment Status ICMJE .Completed .Enrollment ICMJE .Completion Date .February 2011 .Primary Completion Date .February 2011 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "90.490036"}
{"text": "Steering committee Professor Peter Friend ( Chair )Dr Richard Haynes ( Clinical Coordinator )Professor Colin Baigent Dr Paul Harden Dr Martin Landray .Page 14 .", "label": "", "metadata": {}, "score": "90.96657"}
{"text": "All authors read and approved the final manuscript .Acknowledgements We thank Ms Ruth Davis ( study administrator ) for coordinating the trial .We also thank the staff at each of the sites who have recruited and cared for the trial participants .", "label": "", "metadata": {}, "score": "91.23488"}
{"text": "Dr Lisa Blackwell ( statistician ) .Collaborators .University Hospitals Birmingham NHS Foundation Trust : A Sharif , L Fifer , C Waite , N Walmsley - Allen .", "label": "", "metadata": {}, "score": "92.27757"}
{"text": "Sirolimus is a macrocyclic lactone , and has a different mechanism of action to CNIs .It blocks the mammalian target of rapamycin pathway , thus inhibiting cellular proliferation .", "label": "", "metadata": {}, "score": "92.695465"}
{"text": "Copyright .\u00a9 Schiffer et al . ; licensee BioMed Central Ltd. 2012 .This article is published under license to BioMed Central Ltd. February 2011 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "92.80378"}
{"text": "160 - 168 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .248 , no .4 , pp .", "label": "", "metadata": {}, "score": "92.81699"}
{"text": "Effect was calculated as risk ratio ( RR ) and 95 % confidence interval .Quantitative variables by groups were evaluated with .SPSS v. 13.0 software was used in statistical analysis ( Chicago , Illinois ) .", "label": "", "metadata": {}, "score": "92.9368"}
{"text": "The device is made from a graft ( an artificial vessel ) which is surrounded on the outside by a metal mesh - like form .", "label": "", "metadata": {}, "score": "93.028175"}
{"text": "Kirk AD , Mannon RB , Kleiner DE , Swanson JS , Kampen RL , Cendales LK , Elster EA , Wakefield T , Chamberlain C , Hoffmann SC .", "label": "", "metadata": {}, "score": "93.55709"}
{"text": "Alberta Transplant Applied Genomics Centre , University of Alberta .Department of Pharmacy , Hannover Medical School .Institute for Clinical Pharmacology , Hannover Medical School .", "label": "", "metadata": {}, "score": "94.10623"}
{"text": "Leeds Teaching Hospitals NHS Trust : C Newstead , R Baker , E Giddings , R Wheatley , S Turner , K Tobin .Royal Liverpool and Broadgreen University Hospital Trust : A Hammad , S Heyworth .", "label": "", "metadata": {}, "score": "94.18112"}
{"text": "CB and ML contributed to the study design and coordination .All authors read and approved the final manuscript .Freeman Hospital .Oxford Transplant Centre , Churchill Hospital , Headington .", "label": "", "metadata": {}, "score": "94.601456"}
{"text": "Ann Intern Med . 1999;Vol .[ Cross Ref ] [ PubMed ] 26 .Mulay AV , Cockfield S , Stryker R , Fergusson D , Knoll GA .", "label": "", "metadata": {}, "score": "94.75959"}
{"text": "Campath and sirolimus in tolerance .The combination of Campath and sirolimus may enable exposure to CNIs to be reduced or eliminated .This could be favorable because CNIs are nephrotoxic and may interfere with tolerogenesis [ 15 ] .", "label": "", "metadata": {}, "score": "96.101685"}
{"text": "Patients with severe diarrhea , vomiting , active peptic ulcer , or gastrointestinal disorder that may affect the absorption of tacrolimus .Patients with any form of current substance abuse , psychiatric disorder , or a condition that , in the opinion of the investigator , may invalidate communication with the investigator .", "label": "", "metadata": {}, "score": "96.25863"}
{"text": "Active Comparator : Prograf ( tacrolimus ) .Prograf \u00ae capsules , twice daily ( Astellas Pharma US , Deerfield IL ) .Intervention : Drug : Prograf .", "label": "", "metadata": {}, "score": "96.78828"}
{"text": "Mr Sanjay Sinha .Mr Chris Watson .Data monitoring committee .Professor Sir Peter Morris ( chair ) .Professor Keith Wheatley .Dr Daniel Abramowicz .", "label": "", "metadata": {}, "score": "96.84015"}
{"text": "University Hospital of Wales : A Asderakis , Y Webley .University Hospitals Coventry and Warwickshire NHS Trust : N Krishnan , R Higgins .Royal Infirmary of Edinburgh : M Akyol , J Davidson , J Steven .", "label": "", "metadata": {}, "score": "96.84544"}
{"text": "T. Feldkamp , U. Kunzendorf , ( Department of Nephrology and Hypertension , University Hospital Schleswig - Holstein , Campus Kiel , Kiel , Germany . )", "label": "", "metadata": {}, "score": "96.85867"}
{"text": "10.1681/ASN.2006101143 .View Article .Copyright .\u00a9 Haynes et al . ; licensee BioMed Central Ltd. 2013 .This article is published under license to BioMed Central Ltd. Links .", "label": "", "metadata": {}, "score": "99.250534"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable .Page 2 .Colin Baigent : colin.baigent@ctsu.ox.ac.uk .Paul Harden : paul.harden@ouh.nhs.uk .", "label": "", "metadata": {}, "score": "101.22481"}
{"text": "Freeman Hospital , Newcastle - upon - Tyne Hospitals NHS Foundation Trust : N Sheerin , M Playford , B Boughen .City Hospital , Nottingham University Hospitals NHS Trust : K Rigg , C Byrne , A Boswell .", "label": "", "metadata": {}, "score": "102.11576"}
{"text": "Derriford Hospital , Plymouth Hospitals NHS Trust : P Rowe , M Coles , C Pickering .Portsmouth Hospitals NHS Trust : P Gibbs , L Watkins , F Williams .", "label": "", "metadata": {}, "score": "102.87454"}
{"text": "LCP - Tarco ( tacrolimus ) tablets provided in 0.5 mg , 1 mg , 2 mg , and 5 mg tablets .Other Names : . tacrolimus .", "label": "", "metadata": {}, "score": "103.63057"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. Solez , R. B. Colvin , L. C. Racusen , et al . , \" Banff ' 05", "label": "", "metadata": {}, "score": "103.65569"}
{"text": "Guy 's and St Thomas ' NHS Foundation Trust : P Chowdhury , J Watkins .Hull and East Yorkshire Hospitals NHS Trust : S Bhandari , K James , H Stark , T Cathcart .", "label": "", "metadata": {}, "score": "106.60018"}
{"text": "David Lewis : david.lewis@ctsu.ox.ac.uk .Iain Macdougall : iain.macdougall@nhs.net .Chidambaram Nathan : Chidambaram.nathan@sth.nhs.uk .James Neuberger : james.neuberger@nhsbt.nhs.uk .Chas Newstead : chas.newstead@leedsth.nhs.uk .Ravi Pararajasingam : ravi.pararajasingam@cmft.nhs.uk .", "label": "", "metadata": {}, "score": "111.18597"}
{"text": "Keith Rigg : keith.rigg@nuh.nhs.uk .Peter Rowe : peter.rowe1@nhs.net .Adnan Sharif : adnan.sharif@uhb.nhs.uk .Neil Sheerin : neil.sheerin@newcastle.ac.uk .Sanjay Sinha : sanjay.sinha@ouh.nhs.uk .Chris Watson : cjew2@cam.ac.uk .", "label": "", "metadata": {}, "score": "112.33102"}
{"text": "1 Department of Medicine , Mayo Clinic , 5777 East Mayo Boulevard , Phoenix , AZ 85054 , USA 2 Department of Surgery , Mayo Clinic , Phoenix , AZ 85054 , USA 3 Department of Pathology , Mayo Clinic , Phoenix , AZ 85054 , USA .", "label": "", "metadata": {}, "score": "112.75552"}
{"text": "Academic Editor : Eric Thervet .Copyright \u00a9 2011 R. L. Heilman et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "113.27338"}
{"text": "Murat Akyol : murat.akyol@ed.ac.uk .Argiris Asderakis : argiris.asderakis@wales.nhs.uk .Alex Baxter : alex.baxter@ctsu.ox.ac.uk .Sunil Bhandari : sunil.bhandari@hey.nhs.uk .Paramit Chowdhury : paramit.chowdhury@gstt.nhs.uk .Marc Clancy : marc.clancy@ggc.scot.nhs.uk .", "label": "", "metadata": {}, "score": "114.02429"}
{"text": "Received 5 April 2013 ; Accepted 6 August 2013 .Copyright \u00a9 2013 Isabel P\u00e9rez - Flores et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "115.15816"}
{"text": "Paul Gibbs : paul.gibbs@porthosp.nhs.uk .Abdul Hammad : abdul.hammad@rlbuht.nhs.uk .Will Herrington : will.herrington@ctsu.ox.ac.uk .Kathy Jayne : kathy.jayne@ctsu.ox.ac.uk .Gareth Jones : gareth.jones14@nhs.net .Nithya Krishnan : nithya.krishnan@uhcw.nhs.uk .", "label": "", "metadata": {}, "score": "123.03916"}
{"text": "Academic Editor : Alejandro Mart\u00edn - Malo .Copyright \u00a9 2012 Anabela Malho Guedes et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "129.64062"}
